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A B S T R A C T  
 
To assess the efficacy of paclitaxel-coated angioplasty balloons in prolonging the survival time of 
target lesion primary patency in arteriovenous fistulas, we designed an investigator-led multi-centre 
randomised controlled trial with follow up time variable and for a minimum of one year. Patients 
with an arteriovenous fistula who were undergoing an angioplasty for a clinical indication were 
included. Patients with one or more lesions outside the treatment segment were excluded. 
Following successful treatment with a high-pressure balloon, 212 patients were randomised. In the 
intervention arm, the second component was insertion of a paclitaxel-coated balloon; and in 
the control arm, an identical procedure was followed, but using a standard balloon. The primary 
endpoint was time to loss of clinically-driven target lesion primary patency. Primary analysis 
showed no evidence for a difference in time to end of target lesion primary patency between 
groups: hazard ratio (95% confidence interval) = 1.18 (0.78, 1.79), p=0.440. There were no 
significant differences for any secondary outcomes, including patency outcomes and adverse 
events. This study demonstrates no evidence that paclitaxel-coated balloons provide benefit, 
following standard care high-pressure balloon angioplasty, in the treatment of arteriovenous 
fistulas. In view of the benefit suggest by other trials, the role of paclitaxel-coated angioplasty 
balloons remains uncertain. Trial registration: ISRCTN14284759. 
 
 




Complications of vascular access are an important cause of morbidity and mortality in 
haemodialysis patients 1. It is widely accepted that an arteriovenous fistula (AVF) is the optimal 
form of vascular access with better patency and lower infection rates than arteriovenous grafts 
(AVGs) and central venous catheters (CVCs) 2. The initial therapy for a stenosis in an AVF is 
balloon angioplasty with high pressure as needed 3. A major concern however is the longevity of 
this effect. Retrospective studies have reported post-intervention primary patency rates of around 
60-70% at 6 months and 40-50% at one year 4-10. Hence more durable interventions are required 
to reduce restenosis rates.  
 
There has been recent interest in the use of paclitaxel-coated balloons to improve patency rates 
following angioplasty of AVFs. The role of paclitaxel-coated balloons has been established in the 
coronary and peripheral arterial circulations 11,12.   A number of small studies have explored the 
potential in arteriovenous fistulas 13-17.  These included studies with AVGs in addition to AVFs16,17, 
and a study in central venous stenosis13. Two larger randomised controlled trials in arteriovenous 
fistulas have been performed.  One of these included 148 lesions and had an angiographic rather 
than clinical primary endpoint 18. The other randomised 132 lesions and had an ultrasonographic 
endpoint 19. In this second study, 48% of lesions contained an endovascular stent which 
complicates interpretation of the results.  In both of these studies, more than one lesion per 
participant was included in the trial in some cases, which means that the observations were not 
independent.    
 
Two large industry-sponsored randomised controlled trials have been performed and these provide 
the highest quality evidence to date. The first, by Treretola et al, enrolled 285 patients with AVFs 
from 23 centres 20,21. There was no evidence that paclitaxel-coated balloon–assisted angioplasty 
was more effective at the primary end point, patency survival at 180 days, compared with 
conventional angioplasty. A second industry sponsored study, by Lookstein et al, enrolled 330 
patients from 29 sites 22.  The results showed that the primary endpoint of target lesion primary 
patency at 6 months was significantly greater in those treated with paclitaxel-coated balloons 
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(82.2% v 59.5%). The PAVE trial is the first investigator-led large scale randomised controlled trial 






Patients and Trial Design 
We performed a randomised controlled trial and aimed to recruit 211 patients (aged ≥ 18), referred 
with a clinical indication for angioplasty of an arteriovenous fistula, from 20 UK centres.  Eligible 
patients were randomised (1:1) post-fistuloplasty to inflation of a second low-pressure balloon 
which was either paclitaxel-coated or standard (non-coated) by the King’s Clinical Trials Unit using 
a web-based system. Randomisation was minimised according to the Interventional Radiologist 
performing the procedure and two binary factors: previous radiological intervention (yes/no); and 
patient on haemodialysis at study entry (yes/no). The allocation was masked from patients, the 
clinicians responsible for referral to Interventional Radiology, and the research team including trial 
statisticians. The treating radiologist could not be masked to treatment allocation due to the 
appearance of the paclitaxel-coated balloon.  
 
If the access circuit contained synthetic graft material or stents, synchronous lesion(s) outside the 
treatment segment, thrombosis, central vein stenosis or residual stenosis ≥ 30% after high-
pressure balloon fistuloplasty, the patient was excluded23. Protocol changes in March 2016 and 
July 2016 broadened the eligibility criteria to include in turn, patients who had not yet started 
haemodialysis and patients with a treatment segment containing one or more lesions that could be 
treated with a single drug-coated balloon up to 120mm in length. These changes were made to aid 
recruitment, whilst maintaining the requirement for an absence of lesions outside the treatment 
segment, which was a unique feature of the trial. A log of changes to inclusion and exclusion 
criteria is available in supplementary material S1 with trial oversight detailed in supplementary 
material S2.  Full details of inclusion and exclusion criteria are also in the original and final 
protocols (supplementary material S7). Patients were followed up for a minimum of one year, and 
all patients continued in the study until the last patient had completed one year of follow up.  All 
patients gave informed consent, and the trial was approved by the London-Chelsea Research 
Ethics Committee 15/LO/0638.  
 
Treatments 
Following the pre-procedure fistulogram the operating radiologist assessed if the patient remained 
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eligible. For all patients the treatment had two components. Firstly, the fistuloplasty procedure was 
performed with a high-pressure balloon (Bard Dorado), with inflation up to 24 atmospheres to 
ensure obliteration of the lesion waist, according to the study protocol. Following this, inclusion and 
exclusion criteria were rereviewed prior to randomisation. In the intervention arm, the second 
component was insertion of a paclitaxel-coated balloon (Bard Lutonix); and in the control arm, an 
identical procedure was followed, but using a standard balloon (Bard Ultraverse). 
 
Outcomes 
The primary endpoint was time (days) to loss of target lesion primary patency. This was defined as 
patency with no re-intervention to the area 5 mm proximal to, within, and 5 mm distal to, the index 
treatment segment.  Target lesion primary patency ended when any of the following occurred: (a) 
clinically driven re-intervention to the treatment segment; (b) thrombotic occlusion that includes the 
treatment segment; (c) surgical intervention that excludes the treatment segment from the access 
circuit; (d) abandonment of the AVF due to an inability to retreat the treatment segment.  In order 
to minimise bias, a different interventional radiologist to the one who performed the index 
procedure performed repeat procedures whenever possible.  Secondary patency endpoints were 
time to loss of access circuit primary patency, and time to loss of access circuit cumulative 
patency.  Access circuit primary patency ended when any of the following occurred: (a) access 
circuit thrombosis, (b) an intervention (either radiological or surgical) anywhere in the access 
circuit, or (c) the access circuit is abandoned due to an inability to treat any lesion.  Access circuit 
cumulative patency ends when the AVF is abandoned, regardless of radiological or surgical 
intervention, with or without a thrombosis event. Multiple/repetitive treatments for stenoses that 
restore patency are compatible with cumulative patency.  Other pre-specified secondary endpoints 
were: angiographically determined late lumen loss (mm), rate of binary angiographic re-stenosis 
(%), procedural success (stenosis ≤30% at completion fistulogram II), number of thrombosis 
events, fistula interventions, adverse events during follow-up, and patient quality of life assessed 
using POS-S renal scores and EQ-5D-5L scales at 6- and 12-months post randomisation. Further 
detail on the primary and secondary endpoint definitions are in the original and final protocols 
(supplementary material S7).  Angiographic secondary endpoints core lab analysis was performed 




Statistics and analysis 
The sample size and power calculations have been described fully in the published protocol 23 and 
in the statistical analysis plan which was signed off prior to database lock. To test the superiority of 
the paclitaxel-coated balloon compared to the standard balloon in time to loss of target lesion 
primary patency (TLPP), Cox proportional-hazards regression was used with treatment group and 
the two binary minimisation factors as covariates. The third minimisation factor, interventional 
radiologist performing the study procedure, was not adjusted for as this would not allow enough 
degrees of freedom. Analysis was by intention to treat. Patients were censored if: they had TLPP 
survival at the end of follow up; or received a renal transplant, switched to peritoneal dialysis, died 
or withdrew from further data collection before reaching the primary endpoint, prior to the study 
end. Schoenfeld residuals were assessed to test whether the proportional-hazards assumption 
was violated; and an interaction term between treatment group and (log)time was considered to 
allow for variable follow-up time effects, if they existed. Multiple imputation was considered if 
numbers of patients non-compliant with study treatment or lost to follow-up were notable or uneven 
across treatment groups 
 
Planned secondary and sensitivity analyses included: an adjusted analysis of the primary outcome 
to evaluate the impact of pre-specified baseline covariates on the estimated treatment effect; and 
an analysis using deaths (not relevant to primary endpoint) and transplantation as competing risks 
rather than censored events to evaluate the influence of the competing events from preventing the 
primary endpoint being observed. For the former, the baseline variables were: ethnicity; age; 
diabetes diagnosis; smoking history; total time (quartiles) on haemodialysis; type of native fistula 
(where the one patient with radial ulna loop was excluded); previous surgical intervention to the 
access circuit; and location of stenosis (where the smallest two categories, cephalic arch and after 
cephalic arch but not beyond the thoracic inlet, were merged due to low sub-group numbers).  
 
Time to event secondary outcomes were analysed using the same Cox proportional-hazards 
regression. Continuous outcomes employed multiple linear regression, again adjusting for the two 
binary minimisation factors, as well as baseline measures of the outcome, if relevant. Count 
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outcomes (checked for over-dispersion) were analysed using negative binomial regression, with 
time in trial set as the exposure period. Results are reported as hazard ratios, regression 
coefficients, odds ratios, or incidence rate ratios, with 95% confidence intervals, where appropriate. 
Kaplan-Meier survival curves were constructed by treatment group to illustrate the time to loss of 
the three patency endpoints.  Adverse events were categorised into relevant types for this patient 
population (for example, access-related or not), and a stacked bar-chart of maximum severity was 
used to visually compare treatment groups where patients had reported at least one event.  







Between 16 November 2015 and 4 October 2018, 212 patients from 20 UK centres 
(supplementary material S3) were randomised into the trial (106 paclitaxel-coated balloon and 106 
standard balloon) (Figure 1). The trial ended on 4 October 2019 when all patients had completed 
at least one year of follow up. Baseline patient demographics and medical history are reported in 
Table 1 and supplementary material S4-S5 (smoking, renal replacement therapy history and 
quality of life).  The proportion of patients in both the paclitaxel-coated and standard balloon 
groups who were male (63.2 and 57.5%), Caucasian (77.4% and 67.9%), had diabetes (54.7% 
and 43.3%), or coronary artery disease (23.6% and 28.3%) reflects the population receiving 
haemodialysis in the UK, as does the mean age (66.9 and 64.1). Although we included patients 
who had not yet started dialysis, the large majority (88.7% and 91.5%) were receiving 
haemodialysis. In 79.2% and 77.4% of cases the fistula had been used. In the remainder, the 
intervention was performed to aid fistula maturation or blood flow prior to use for haemodialysis.  
There was a range of indications for intervention that are in keeping with clinical experience (Table 
1). All characteristics including fistula type and lesion location appeared balanced between the 
groups.  A specific high-pressure balloon (Bard Dorado) is named in the protocol. There were no 
differences in frequency of its use or in the lengths of the high-pressure and treatment balloons 
used. Two patients did not receive their allocated treatment (paclitaxel-coated balloon) because 
they were found to be ineligible after randomisation, but they were both included in the intention-to-
treat analysis (denoted by dashed lines in Figure 1).  The inflation time of the treatment balloon 
was as specified in the protocol in 100% and 94% of cases in the paclitaxel-coated and standard 
balloon groups, respectively.  There were no other major protocol deviations.  Six patients 
withdrew from further data collection during follow-up and were censored in the primary analysis; 
no patients were lost to follow-up. Multiple imputation was not necessary.  
 
Outcomes 
Only one (out of a possible three) interim analysis was conducted during the trial, when number of 
primary endpoint events had reached 27 and recruitment was still ongoing. The independent data 
monitoring and ethics committee reviewed partially-masked results and recommended the 
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continuation of the trial as the pre-specified futility and efficacy boundaries had not been met. At 
the end of the study 89 patients had reached the primary endpoint loss of target lesion primary 
patency (TLPP) over the trial period, with similar numbers in each treatment group: 44 in the 
paclitaxel-coated balloon group and 45 in the standard balloon group (Table 2; Figure 2A). For 
those who lost TLPP, the median (IQR) times to event (in days) were similar at 159 (102-234) and 
215 (145-340). There was no evidence of a difference in time to loss of TLPP in the paclitaxel-
coated balloon group compared to the standard balloon using Cox proportional-hazards regression 
(hazard ratio 1.18 (95% CI: 0.78, 1.79), p=0.440; Table 2), and there was no suggestion that 
variable follow-up time effects needed to be adjusted for. The results were not appreciably different 
in the secondary adjusted analysis, including baseline covariates (HR (95% CI): 1.11 (0.69, 1.78), 
p=0.664), or in the competing risks sensitivity analysis (sub-hazard ratio (95% CI): 1.06 (0.67, 
1.67), p=0.805). All patients randomised in the current trial were included in the final intention-to-
treat survival analysis and no patients were lost to follow-up so there were no missing primary 
outcome data.   
 
At 6 months the TLPP was 71.7% (66/92 patients) in the paclitaxel-coated balloon group, 
compared to 84.5% (82/97 patients) in the standard balloon group. By 12 months, these figures 
were 52.5% (44/81) and 58.8% (50/85) respectively. Radiological reintervention was the reason for 
meeting the primary endpoint in 31 (70.5%) and 34 (75.6%) of the paclitaxel-coated and standard 
balloon groups, respectively. In only one quarter (17/65) of cases was the primary endpoint met 
due to reintervention by the interventional radiologist who performed the index procedure, which 
was evenly split across treatment groups (8 paclitaxel-coated and 9 standard balloon). Otherwise, 
the primary endpoint was reached due to: thrombosis (3 (6.8%) and 5 (11.1%)); surgical 
intervention (5 (11.4%) and 1 (2.2%)) ; or a decision to abandon the fistula  (5 (11.4%) and 5 
(11.1%)) of paclitaxel-coated and standard balloon groups, respectively. Out of 46 fistulas that had 
not yet been used for dialysis, only 10 (21.7%) of these were abandoned (having reached the end 
of access circuit cumulative patency) during follow up 
 
For the two time to event secondary outcomes of loss of access circuit primary and cumulative 
patency there was again no evidence for a difference between the treatment groups: HR (95% CI): 
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1.06 (0.71, 1.59), p=0.764; and HR (95% CI): 1.30 (0.67, 2.55), p=0.438, respectively  (Table 2; 
Figures 2B-2C). None of the other secondary outcomes demonstrated a treatment effect of 
paclitaxel-coated balloon compared to standard balloon: (Table 2) mean late lumen loss was 
1.49mm and 1.48 mm; binary restenosis at 6 months occurred in 62.5% and 57.7%; and 
procedural success (residual stenosis <30% after treatment with paclitaxel-coated or standard 
balloon) occurred in 98.1% and 92.5%.  Data for the number of thrombosis events, fistula 
interventions, adverse events, and quality of life at 6 and 12 months are also given in Table 2 and 
were similar in both groups. Further data on quality of life at 6 and 12 months are given in 
supplementary material S5 with a list of adverse events in supplementary material S6. All relevant 
model assumptions were checked and considered compliant. Finally, Figure 3 illustrates the 
maximum severity for reported adverse events, where a patient had at least one event for each 
respective category. In total, 216 events were reported during the study (113 paclitaxel-coated 







The aim of the PAVE trial was to assess the efficacy of paclitaxel-coated balloons in the treatment 
of arteriovenous fistulas used to deliver haemodialysis.  Although a number of earlier studies have 
suggested a possible benefit 13-19, there are only two previous large randomised trials, with clinical 
endpoints, addressing this question 20 22. The first published large-scale trial by Treretola et al, 
using the same paclitaxel-coated balloon as the current trial, also failed to demonstrate a 
difference between arms in their pre-specified primary endpoint, target lesion primary patency at 
180 days 20,  but there was a significant difference at 210 days in an exploratory analysis.  A later 
publication from this same study showed a significant difference at 12 months but not at 24 months 
21.  Therefore, uncertainty remained regarding the efficacy of paclitaxel-coated balloons for this 
indication.    
 
A recent study by Lookstein et al that also used a binary primary endpoint of target lesion primary 
patency at 6 months did find evidence of a benefit for paclitaxel-coated balloons 22. One possible 
explanation for the contrasting result in this and the current study is the use of a different treatment 
balloon. The Lutonix balloon used in the current study used a coating of paclitaxel, sorbitol and 
polysorbate with a drug dose density of 2μg/mm2. In contrast the IN.PACT balloon used by 
Lookstein et al is loaded with a higher concentration of paclitaxel (3.5 µg/mm2) and uses a urea-
based excipient.  These devices were compared in a pig femoral artery angioplasty model 24 .  
There was no comparison of the amount of drug delivered to the artery. However, there was a 
higher paclitaxel content in non-target tissues and evidence of downstream embolic crystalline 
material with the IN.PACT balloon.  Another study showed greater drug loss from the IN.PACT 
balloon than from the Lutonix balloon with dry handling or inflation 25.  Therefore, the higher drug 
dose density on the IN.PACT balloon does not necessarily result in a higher drug dose being 
delivered to the target lesion because a higher proportion may be lost before insertion or deposited 
in non-target tissues. 
 
When recruitment to the PAVE trial began in November 2015, the instructions for the paclitaxel-
coated balloon recommended an inflation time of 30 seconds and 60 seconds was stated in the 
protocol to ensure this was exceeded.  Data collected during the trial included a question asking if 
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an inflation time of more than 60 seconds was achieved (yes or no).  From March 2018, when 75% 
of patients had been randomised, study sites were asked to inflate for a minimum of 120 seconds 
following a change in the manufacturer’s instructions.  The data in table 1 showed good adherence 
to the protocol with inflation recorded as more than 60 seconds in 97% of patients, with no 
evidence of a difference between groups. The manufacturer’s recommendation for an increase in 
inflation time is based on preclinical data in a pig femoral artery angioplasty model, but there are 
no data given comparing 60 and 120 seconds25.  The fact that the current study used the Lutonix 
balloon with a minimum inflation time of 60 seconds, does not necessarily mean that a lower dose 
of paclitaxel was delivered to the target lesion that occurred in the study by Lookstein et al using 
the IN.PACT balloon22. However, we acknowledge that this is a possible explanation for the 
differing results.   
 
A limitation of the PAVE trial is that it was not a fully blinded trial. It was impossible to ensure that 
treating radiologists were blinded to treatment allocation due to the appearance of the paclitaxel-
coated balloon. However, all other investigators as well as the patients were blinded and this 
minimised the chance of bias. Furthermore, it is more likely that any small introduction of bias 
would have led to a positive outcome, rather than the negative result that we found.  Patients were 
invited to attend a 6 month protocol fistulogram. If clinically-indicated imaging or intervention was 
planned then the protocol fistulogram was not requested. Radiologists were instructed not to 
intervene if subclinical stenosis were detected at the protocol fistulogram and this was adhered to 
in all cases. Therefore, the protocol fistulogram had no effect on the primary outcome measure of 
clinically-driven TLPP. 
 
A number of aspects in the design of the current trial further reduced the possibility of bias. 
Reintervention was only performed after referral for a clinical indication by a member of the clinical 
team blinded to the treatment allocation. Clinically driven radiological reintervention was the 
predominant reason for meeting the primary endpoint.  Reintervention was performed by a 
different interventional radiologist whenever possible. Images from radiological interventions 
leading to loss of target lesion primary patency were reviewed by an interventional radiologist from 
a different study site or the core laboratory in all cases. In cases where the primary endpoint was 
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reached due to surgical intervention or a decision to abandon the fistula, the decision would not 
have been influenced by knowledge of treatment allocation.  
 
The 6-month TLPP in the control group was 71.1% in the current trial and this is higher than those 
reported in the other published trials20,22 and most institutional case series 4-10. The TLPP in the 
control arm of the study by Lookstein et al was only 59.5% at 6 months22.  This underlines the 
value of a good balloon fistuloplasty in maintaining patency.  If a good result is achieved with a 
high-pressure plain balloon, then there may be little or no benefit in using an additional paclitaxel-
coated balloon.  This may be why paclitaxel-coated balloons were shown to improve the outcome  
in the study by Lookstein et al22, but not in the current study. An increase in mortality has been 
linked with the use of paclitaxel coated balloons in peripheral vascular disease26.  An effect was 
seen after 2 years but not after one year and the mechanism was not clear.  Although we saw 
more deaths in patients treated with paclitaxel-coated balloons compared with the control group 
(Figure 3), the difference was small, and the numbers too low to draw any conclusions.  
 
In contrast to the previous trials 20,22 only patients with a single lesion or tandem lesions that could 
be treated by a single drug-coated balloon, were eligible in the current trial. This is unlikely to 
explain the lower event rate in the current trial because previous data suggests that post-
intervention access circuit primary patency is similar in patients with multiple or single lesions 7. 
However, stenoses at multiple sites in the access circuit is a common finding and deciding which is 
clinically most significant can be subjective. We therefore only included patients with a stenosis at 
a single site in the circuit in order to be sure that this lesion was responsible for the clinical problem 
leading to intervention.  In order to maintain recruitment of patients with a single treatment 
segment, we included fistulas that had not yet been used for dialysis.  However, few of these were 
abandoned (having reached the end of access circuit cumulative patency) during follow up. 
Therefore, a high rate of primary failure of fistula maturation was unlikely to affect the outcome.  
We consider that the application of a drug coated balloon to a single treatment segment to be a 
unique feature and a strength of the current study20,22.   The aim was to investigate the efficacy of 
paclitaxel-coated balloons and we believe that this increased the rigour with which we were able to 





In conclusion, the current results provide no evidence of an additional benefit from paclitaxel-
coated balloons compared to standard balloons when used after a clinically driven high-pressure 
balloon angioplasty in arteriovenous fistulas. We did not observe any indication of an early 
treatment effect in the data, and all of the pre-specified outcomes support the same conclusion.  
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 n (%) unless stated 
Age mean (SD) 66.9 (12.7)  64.1 (13.3)  
Sex  Male 67 (63.2) 61 (57.5) 
Ethnicity  White 82 (77.4) 72 (67.9) 
Black 9 (8.5) 16 (15.1) 
Asian 11 (10.4) 14 (13.2) 
Mixed/Other 4 (3.8) 4 (3.8) 
Current diabetes diagnosis Yes 58 (54.7) 46 (43.4) 
Coronary artery disease Yes 25 (23.6) 30 (28.3) 
Peripheral vascular disease Yes 13 (12.3) 18 (17.0) 
Currently on haemodialysis †  Yes 94 (88.7) 97 (91.5) 
Location of fistula (arm) Left  84 (79.2) 72 (67.9) 
Type of native fistula Radio-cephalic 43 (40.6) 39 (36.8) 
Brachio-cephalic 52 (49.1) 55 (51.9) 
Basilic vein transposition 10 (9.4) 12 (11.3) 
Radial ulna loop 1 (0.9) NA 
Time since fistula formed (months) (n=210) median (IQR)  23 (8-40) 16 (7.5-40.5) 
Fistula been used at least once  Yes 84 (79.2) 82 (77.4) 
Time since fistula was first used (months) 
(n=166) ‡ median (IQR) 21 (7-41) 15 (5-36) 
Current access circuit previously had a 
thrombosis Yes 7 (6.6) 3 (2.8) 
Previous surgical interventions to the current 
access circuit  Yes 20 (18.9) 24 (22.6) 
Previous radiological intervention in access 
circuit † Yes 35 (33.0) 38 (35.8) 
Location of stenosis Juxta-anastomotic 51 (48.1) 43 (40.6) 
Venous segment* 40 (37.7) 51 (48.1) 
Cephalic arch 15 (14.2) 10 (9.4) 
From cephalic arch to 
thoracic inlet 
- 2 (1.9) 
Primary indication for the index procedure Inadequate dialysis 12 (11.3)  6 (5.7)  
Poor blood flow 37 (34.9)  37 (34.9)  
Prolonged bleeding 5 (4.7)  9 (8.5)  
High venous pressure 9 (8.5)  11 (10.4)  
Low arterial pressure -  1 (0.9)  
Difficulty needling 25 (23.6)  20 (18.9)  
Immature fistula 5 (4.7)  6 (5.7)  
Not specified 11 (10.4)  13 (12.3)  
Other 2 (1.9)  3 (2.8)  
High pressure balloon type as per protocol  Yes 87 (82.1) 85 (80.2) 
High pressure balloon length (cm) mean (SD) 4.6 (1.7) 4.6 (1.8) 
Treatment balloon length (cm) mean (SD) 6.8 (2.0) 6.6 (1.9) 
Treatment balloon inflation time > 1 minute Yes 104/104 (100) 100/106 (94) 
 
†Minimisation factor; ‡If used at least once prior to randomisation; SD: standard deviation; IQR: inter-quartile 








*For those that required an intervention before 6 months, mean days to intervention were 125.1 in the 
paclitaxel-coated balloon group (n=23) and 149.6 in the standard balloon group (n=17); IQR: inter-quartile 
range; SD: standard deviation; HR: hazard ratio; OR: odds ratio; IRR: incidence rate ratio; EQ-5D-5L VAS: 











Primary outcome n (%) unless stated   
Time to loss of target 
lesion primary patency  
Endpoint reached 44 (41.5) 45 (42.5) 
HR: 1.18 (0.78, 1.79) 0.440 
median days (IQR) 159 (102-234)  215 (145-340)  
Secondary outcomes n (%) unless stated   
Time to loss of access 
circuit primary patency 
Endpoint reached 47 (44.3) 51 (48.1) 
HR: 1.06 (0.71, 1.59) 0.764 
median days (IQR) 160 (94-268) 203 (139-324) 
Time to loss of access 
circuit cumulative 
patency 
Endpoint reached 19 (17.9) 16 (15.1) 
HR: 1.30 (0.67, 2.55) 0.438 
median days (IQR) 201 (85-359) 270.5 (173.5-383.5) 
Angiographically 
determined late lumen 
loss (mm)*  
mean (SD) 1.49 (1.55) n=55 
1.48 (1.68) 






n=52 OR: 1.23 (0.56, 2.71) 0.600 
Procedural success Yes 102 (98.1) n=104 
98 (92.5) 
n=106 
OR: 4.16 (0.85, 
20.37) 0.079 
Number of thrombosis 
events 
0 87 (82.1) 91 (85.8) 
IRR: 1.58 (0.70, 3.58) 0.273 1 16 (15.1) 10 (9.4) 
>1 3 (2.8) 5 (4.7) 
Number of fistula 
interventions 
0 55 (51.9) 53 (50.) 
IRR: 1.26 (0.85, 1.87) 0.245 1 25 (23.6) 32 (30.2) 
>1 26 (24.5) 21 (19.8) 
Number of adverse 
events median (IQR) 0 (1-2) 0 (0-2) 
IRR: 1.26 (0.78, 2.04) 0.338 
Health today (EQ-5D-5L 




n=74 0.32 (-5.25, 5.89) 0.909 
Health today (EQ-5D-5L 




n=47 -1.79 (-9.40, 5.81) 0.640 
POS-S Renal 6-months mean (SD) 13.6 (10.8) n=68 
13.6 (8.6) 
n=72 1.01 (-1.59,3.60) 0.443 
POS-S Renal 12-months mean (SD) 13.9 (10.5) n=48 
13.6 (8.1) 








Figure 1.   






Figure 2.   












Figure 3.    
Severity and type of adverse event by treatment group. PC: paclitaxel-coated balloon group; S: standard 
balloon group. This bar chart illustrates the main types of adverse events that were reported by patients 
during follow-up, by treatment group and maximum severity. Patients can be included in more than one type 
of event, but if they experienced a certain event type more than once, then they have only been counted 
once for that event, and the maximum severity that they reported for that type of event has been used. 
Please note: this graph does not include deaths that occurred after patients formally withdrew from the trial; 
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S1 Inclusion and exclusion criteria 
Protocol version 2 (approved 18.8.15, before recruitment started) 
Inclusion criteria  
1. Patients (18 years or over) who have a native AVF in the arm that has been used for 
haemodialysis for at least 12 dialysis sessions 
2. An indication for a fistuloplasty as determined by the local clinical team  
3. The access circuit is free of synthetic graft material or stents  
4. A reduction of vessel diameter of ≥ 50% measured angiographically, and a reference 
diameter of the outflow vein of at least 4 mm and less than the size of the largest available 
drug-coated balloon  
5. A residual stenosis ≤ 30% after plain balloon fistuloplasty  
Exclusion criteria  
1. Patient unable to give informed consent  
2. Patient unwilling or unable to comply with all study-related procedures  
3. Systemic or local (to the fistula) infection treated for less than 10 days prior to the study 
procedure  
4. Synchronous venous lesion, with a reduction of vessel diameter of 50% measured 
angiographically, in the same access circuit  
5. Location of stenosis beyond the thoracic inlet  
6. Thrombosed (failed) dialysis circuit at time of treatment  
7. Women who are breastfeeding, pregnant or are intending to become pregnant or men 
intending to father children, within two years of study treatment  
8. Known hypersensitivity or contraindication to contrast medium which cannot be 
adequately premedicated  
9. Known hypersensitivity or contraindication to paclitaxel  
Protocol version 5 (approved 8.4.16) 
 
Inclusion criteria 1 amended: 
1. Patients (18 years or over) who have a native AVF in the arm  
 
Protocol version 6 (approved 31.8.16) 
Inclusion criteria 6 added: 
6.  A treatment segment, containing one or more lesions, which can be treated with ≤120 
mm of a single drug-coated balloon. 
 
Exclusion criteria 4 amended: 
4. One or more lesions outside the treatment segment, with a reduction of vessel diameter of 
³ 50% measured angiographically, in the same access circuit.  
 
Protocol version 7 (approved 21.3.17) 
 
Exclusion criteria 4 amended again: 
4. One or more lesions outside the treatment segment, with a reduction of vessel diameter of 
³ 50% measured angiographically, in the same access circuit. The patient will also be 
excluded if any lesions outside the treatment segment are treated even if these are <50% 
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S2  Trial Oversight 
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Dublin, Ireland 
Added 25/04/2017 - 
current 
Member Troxler, Max1 
Leeds Teaching Hospital 
NHS Trust 
Original Member 




Member Mitra, Sandip2 
Manchester University 












The Newcastle Upon Tyne 
Hospitals NHS Foundation 
Trust 
Original Member - 
22/07/2016 
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S3 Sites  
Table: Hospital sites (radiologists per site) 
Radiologist performing the treatment was a minimisation factor. 
	
 Paclitaxel- 





1. Bradford (1) 2 2 
2. Cardiff  (2) 5 3 
3. Canterbury  (2) 14 16 
4. Edinburgh  (2) 3 - 
5. Gloucester  (2)  8 8 
6. Guy’s  (9) 21 16 
7. Hull  (3) 4 5 
8. King’s  (4) 4 8 
9. Leicester (1) 2 2 
10. Lister  (2) 11 10 
11. Portsmouth  (2) 5 2 
12. Devon (2) 4 3 
13. Royal London (1) 1 3 
14. Reading (2) 5 4 
15. Royal Free (3) 3 5 
16. Preston (2) 2 3 
17. Brighton (1) 1 1 
18. Sheffield (2) 1 1 
19. St George’s (1) 1 2 





















 n (%) unless stated 
Patient smoking history (n=211) Current  12 (11.4) 16 (15.1) 
Former  37 (35.2) 33 (31.1) 
Never  56 (53.3) 57 (53.8) 
Total accumulated time patient has 
spent on haemodialysis (months; 
quartiles) (n=211) 
0-6 months 29 (27.4) 26 (24.8) 
7-17 months 20 (18.9) 31 (29.5) 
18-39 months 31 (29.2) 23 (21.9) 
40-198 months 26 (24.5) 25 (23.8) 
Previous renal transplant(s) Yes 9 (8.5) 15 (14.2) 
Total accumulated time with a functional 
renal transplant (months) (n=22) 
median (IQR) 77 (25-174) 73.5 (4-204) 
Spent time on peritoneal dialysis Yes 13 (12.3) 19 (17.9) 
Total accumulated time patient has 
spent on peritoneal dialysis (months) 
(n=32) 













EQ-5D-5L [Description of health today]  
Mobility  No problems 29 (28.7) 27 (28.4) 
Slight problems 23 (22.8) 27 (28.4) 
Moderate problems 29 (28.7) 20 (21.1) 
Severe problems 13 (12.9) 18 (18.9) 
Unable to walk about 7 (6.9) 3 (3.2) 
Self-Care No problems 68 (67.3) 60 (63.2) 
Slight problems 17 (16.8) 18 (18.9) 
Moderate problems 7 (6.9) 10 (10.5) 
Severe problems 5 (5.0) 5 (5.3) 
Unable to wash/dress 
myself 
4 (4.0) 2 (2.1) 
Usual Activities No problems 28 (27.7) 32 (33.7) 
Slight problems 32 (31.7) 26 (27.4) 
Moderate problems 22 (21.7) 22 (23.2) 
Severe problems 10 (9.9) 10 (10.5) 
Unable to do usual 
activities 
9 (8.9) 5 (5.3) 
Pain/Discomfort None 44 (43.6) 27 (28.4) 
Slight 28 (27.7) 31 (32.6) 
Moderate 18 (17.8) 29 (30.5) 
Severe  7 (6.9) 7 (7.4) 
Extreme 4 (4.0) 1 (1.1) 
Anxiety/Depression None 66 (65.3) 47 (49.5) 
Slight 20 (19.8) 29 (30.5) 
Moderate 12 (11.9) 17 (17.9) 
Severe  1 (1.0) 2 (2.1) 
Extreme 2 (2.0) - 
Health today (VAS)   
   (0=worst imaginable; 
   100=best imaginable) 






POS-S Renal [How have each of the 17 symptoms affected them and how they have felt 
over past week] (n=191) 
Total score 
   (0=not at all; 
   4=overwhelmingly) 
   Min=0  
   Max=68 







EQ-5D-5L post randomisation 
6-months (n=145) 
Mobility  No problems 17 (24.3) 19 (25.3) 
Slight problems 21 (30.0) 19 (25.3) 
Moderate problems 11 (15.7) 19 (25.3) 
Severe problems 14 (20.0) 12 (16.0) 
Unable to walk about 7 (10.0) 6 (8.0) 
Self-Care No problems 44 (62.9) 42 (56.0) 
Slight problems 10 (14.3) 13 (17.3) 
Moderate problems 5 (7.1) 11 (14.7) 
Severe problems 8 (11.4) 7 (9.3) 
Unable to wash/dress 
myself 
3 (4.3) 2 (2.7) 
Usual Activities No problems 26 (37.1) 24 (32.0) 
Slight problems 15 (21.4) 24 (32.0) 
Moderate problems 11 (15.7) 12 (16.0) 
Severe problems 11 (15.7) 11 (14.7) 
Unable to do usual 
activities 
7 (10.0) 4 (5.3) 
Pain/Discomfort None 28 (40.0) 15 (20.3) 
Slight 18 (25.7) 25 (33.8) 
Moderate 14 (20.0) 22 (29.7) 
Severe  8 (11.4) 10 (13.5) 
Extreme 2 (2.9) 2 (2.7) 
Anxiety/Depression None 40 (57.1) 36 (48.0) 
Slight 16 (22.9) 31 (41.3) 
Moderate 10 (14.3) 6 (8.0) 
Severe  3 (4.3) 2 (2.7) 
Extreme 1 (1.4) - 
12-months (n=95) 
Mobility  No problems 17 (35.4) 9 (19.1) 
Slight problems 10 (20.8) 16 (34.0) 
Moderate problems 9 (18.8) 13 (27.7) 
Severe problems 7 (14.6) 8 (17.0) 
Unable to walk about 5 (10.4) 1 (2.1) 
Self-Care No problems 31 (64.6) 28 (59.6) 
Slight problems 10 (20.8) 12 (25.5) 
Moderate problems 2 (4.2) 6 (12.8) 
Severe problems 3 (6.3) 1 (2.1) 
Unable to wash/dress 
myself 
2 (4.2) - 
Usual Activities No problems 17 (35.4) 13 (27.7) 
Slight problems 15 (31.3) 13 (27.7) 
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Moderate problems 5 (10.4) 14 (29.8) 
Severe problems 4 (8.3) 6 (12.8) 
Unable to do usual 
activities 
7 (14.6) 1 (2.1) 
Pain/Discomfort None 20 (41.7) 15 (31.9) 
Slight 12 (25.0) 15 (31.9) 
Moderate 10 (20.8) 11 (23.4) 
Severe  3 (6.3) 5 (10.6) 
Extreme 3 (6.3) 1 (2.1) 
Anxiety/Depression None 28 (58.3) 24 (51.1) 
Slight 12 (25.0) 19 (40.4) 
Moderate 6 (12.5) 4 (8.5) 
Severe  - - 
Extreme 2 (4.2) - 












S6 List of adverse events 




Paclitaxel-coated balloon Insertion of CVC  0. No 1. Mild 
Paclitaxel-coated balloon Insertion of CVC  0. No 1. Mild 
Paclitaxel-coated balloon Insertion of CVC  0. No 1. Mild 
Paclitaxel-coated balloon Insertion of CVC  0. No 2. Moderate 
Paclitaxel-coated balloon Insertion of CVC  0. No 2. Moderate 
Paclitaxel-coated balloon Insertion of CVC  0. No 2. Moderate 
Paclitaxel-coated balloon Insertion of CVC  0. No 2. Moderate 
Paclitaxel-coated balloon Insertion of CVC  0. No 2. Moderate 
Paclitaxel-coated balloon Insertion of CVC  0. No 2. Moderate 
Paclitaxel-coated balloon Insertion of CVC  0. No 2. Moderate 
Paclitaxel-coated balloon Insertion of CVC  0. No 2. Moderate 
Paclitaxel-coated balloon Insertion of CVC  0. No 2. Moderate 
Paclitaxel-coated balloon Insertion of CVC  1. Yes 2. Moderate 
Paclitaxel-coated balloon Thrombosed access  0. No 1. Mild 
Paclitaxel-coated balloon Thrombosed access  1. Yes 1. Mild 
Paclitaxel-coated balloon Thrombosed access  1. Yes 1. Mild 
Paclitaxel-coated balloon Thrombosed access  1. Yes 2. Moderate 
Paclitaxel-coated balloon Thrombosed access  1. Yes 2. Moderate 
Paclitaxel-coated balloon Thrombosed access  1. Yes 2. Moderate 
Paclitaxel-coated balloon Access-related (other)  0. No 1. Mild 
Paclitaxel-coated balloon Access-related (other)  0. No 1. Mild 
Paclitaxel-coated balloon Access-related (other)  0. No 1. Mild 
Paclitaxel-coated balloon Access-related (other)  0. No 1. Mild 
Paclitaxel-coated balloon Access-related (other)  0. No 1. Mild 
Paclitaxel-coated balloon Access-related (other)  0. No 1. Mild 
Paclitaxel-coated balloon Access-related (other)  0. No 1. Mild 
Paclitaxel-coated balloon Access-related (other)  0. No 2. Moderate 
Paclitaxel-coated balloon Access-related (other)  0. No 2. Moderate 
Paclitaxel-coated balloon Access-related (other)  0. No 3. Severe 
Paclitaxel-coated balloon Access-related (other)  0. No 3. Severe 
Paclitaxel-coated balloon Access-related (other)  1. Yes 1. Mild 
Paclitaxel-coated balloon Access-related (other)  1. Yes 1. Mild 
Paclitaxel-coated balloon Access-related (other)  1. Yes 2. Moderate 
Paclitaxel-coated balloon Access-related (other)  1. Yes 2. Moderate 
Paclitaxel-coated balloon Access-related (other)  1. Yes 3. Severe 
Paclitaxel-coated balloon Access-related (other)  1. Yes 3. Severe 
Paclitaxel-coated balloon Cardiovascular/respiratory  0. No 1. Mild 
Paclitaxel-coated balloon Cardiovascular/respiratory  0. No 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 1. Mild 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 1. Mild 
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Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 1. Mild 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 1. Mild 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 1. Mild 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Paclitaxel-coated balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Paclitaxel-coated balloon Gastrointestinal  1. Yes 3. Severe 
Paclitaxel-coated balloon Foot disease  1. Yes 2. Moderate 
Paclitaxel-coated balloon Foot disease  1. Yes 3. Severe 
Paclitaxel-coated balloon Foot disease  1. Yes 3. Severe 
Paclitaxel-coated balloon Fall/syncope  1. Yes 1. Mild 
Paclitaxel-coated balloon Fall/syncope  1. Yes 2. Moderate 
Paclitaxel-coated balloon Fall/syncope  1. Yes 2. Moderate 
Paclitaxel-coated balloon Fall/syncope  1. Yes 2. Moderate 
Paclitaxel-coated balloon Musculoskeletal  1. Yes 2. Moderate 
Paclitaxel-coated balloon Musculoskeletal  1. Yes 2. Moderate 
Paclitaxel-coated balloon Musculoskeletal  1. Yes 3. Severe 
Paclitaxel-coated balloon Hypertension  1. Yes 3. Severe 
Paclitaxel-coated balloon Bacteraemia  1. Yes 2. Moderate 
Paclitaxel-coated balloon Bacteraemia  1. Yes 2. Moderate 
Paclitaxel-coated balloon Cutaneous  1. Yes 2. Moderate 
Paclitaxel-coated balloon Other  0. No 1. Mild 
Paclitaxel-coated balloon Other  0. No 1. Mild 
Paclitaxel-coated balloon Other  0. No 1. Mild 
Paclitaxel-coated balloon Other  0. No 1. Mild 
Paclitaxel-coated balloon Other  0. No 3. Severe 
Paclitaxel-coated balloon Other  1. Yes 1. Mild 
Paclitaxel-coated balloon Other  1. Yes 1. Mild 
Paclitaxel-coated balloon Other  1. Yes 1. Mild 
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Paclitaxel-coated balloon Other  1. Yes 2. Moderate 
Paclitaxel-coated balloon Other  1. Yes 2. Moderate 
Paclitaxel-coated balloon Other  1. Yes 2. Moderate 
Paclitaxel-coated balloon Other  1. Yes 2. Moderate 
Paclitaxel-coated balloon Other  1. Yes 2. Moderate 
Paclitaxel-coated balloon Other  1. Yes 2. Moderate 
Paclitaxel-coated balloon Other  1. Yes 2. Moderate 
Paclitaxel-coated balloon Other  1. Yes 2. Moderate 
Paclitaxel-coated balloon Other  1. Yes 2. Moderate 
Paclitaxel-coated balloon Other  1. Yes 2. Moderate 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Paclitaxel-coated balloon Death  1. Yes 3. Severe 
Standard balloon Insertion of CVC  0. No 1. Mild 
Standard balloon Insertion of CVC  0. No 1. Mild 
Standard balloon Insertion of CVC  0. No 1. Mild 
Standard balloon Insertion of CVC  0. No 1. Mild 
Standard balloon Insertion of CVC  0. No 1. Mild 
Standard balloon Insertion of CVC  0. No 2. Moderate 
Standard balloon Insertion of CVC  0. No 2. Moderate 
Standard balloon Insertion of CVC  0. No 2. Moderate 
Standard balloon Insertion of CVC  1. Yes 1. Mild 
Standard balloon Thrombosed access  0. No 2. Moderate 
Standard balloon Thrombosed access  1. Yes 1. Mild 
Standard balloon Thrombosed access  1. Yes 2. Moderate 
Standard balloon Thrombosed access  1. Yes 2. Moderate 
Standard balloon Thrombosed access  1. Yes 3. Severe 
Standard balloon Access-related (other)  0. No 1. Mild 
Standard balloon Access-related (other)  0. No 1. Mild 
Standard balloon Access-related (other)  0. No 1. Mild 
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Standard balloon Access-related (other)  0. No 2. Moderate 
Standard balloon Access-related (other)  0. No 2. Moderate 
Standard balloon Access-related (other)  1. Yes 2. Moderate 
Standard balloon Access-related (other)  1. Yes 2. Moderate 
Standard balloon Access-related (other)  1. Yes 2. Moderate 
Standard balloon Access-related (other)  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  0. No 1. Mild 
Standard balloon Cardiovascular/respiratory  0. No 1. Mild 
Standard balloon Cardiovascular/respiratory  1. Yes 1. Mild 
Standard balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  1. Yes 2. Moderate 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Cardiovascular/respiratory  1. Yes 3. Severe 
Standard balloon Gastrointestinal  0. No 1. Mild 
Standard balloon Gastrointestinal  0. No 1. Mild 
Standard balloon Gastrointestinal  1. Yes 1. Mild 
Standard balloon Gastrointestinal  1. Yes 2. Moderate 
Standard balloon Gastrointestinal  1. Yes 2. Moderate 
Standard balloon Gastrointestinal  1. Yes 2. Moderate 
Standard balloon Gastrointestinal  1. Yes 2. Moderate 
Standard balloon Gastrointestinal  1. Yes 2. Moderate 
Standard balloon Gastrointestinal  1. Yes 2. Moderate 
Standard balloon Gastrointestinal  1. Yes 2. Moderate 
Standard balloon Foot disease  0. No 2. Moderate 
Standard balloon Foot disease  0. No 2. Moderate 
Standard balloon Foot disease  1. Yes 2. Moderate 
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Standard balloon Foot disease  1. Yes 2. Moderate 
Standard balloon Foot disease  1. Yes 3. Severe 
Standard balloon Fall/syncope  1. Yes 1. Mild 
Standard balloon Fall/syncope  1. Yes 1. Mild 
Standard balloon Fall/syncope  1. Yes 3. Severe 
Standard balloon Musculoskeletal  1. Yes 2. Moderate 
Standard balloon Musculoskeletal  1. Yes 3. Severe 
Standard balloon Musculoskeletal  1. Yes 3. Severe 
Standard balloon Hypertension  0. No 1. Mild 
Standard balloon Hypertension  0. No 1. Mild 
Standard balloon Hypertension  0. No 1. Mild 
Standard balloon Hypertension  1. Yes 1. Mild 
Standard balloon Hypertension  1. Yes 2. Moderate 
Standard balloon Bacteraemia  1. Yes 2. Moderate 
Standard balloon Bacteraemia  1. Yes 2. Moderate 
Standard balloon Bacteraemia  1. Yes 2. Moderate 
Standard balloon Cutaneous  0. No 1. Mild 
Standard balloon Cutaneous  1. Yes 3. Severe 
Standard balloon Neurological  1. Yes 3. Severe 
Standard balloon Neurological  1. Yes 3. Severe 
Standard balloon Other  0. No 3. Severe 
Standard balloon Other  1. Yes 1. Mild 
Standard balloon Other  1. Yes 2. Moderate 
Standard balloon Other  1. Yes 2. Moderate 
Standard balloon Other  1. Yes 3. Severe 
Standard balloon Other  1. Yes 3. Severe 
Standard balloon Other  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 
Standard balloon Death  1. Yes 3. Severe 





Section S7 Protocols and statistical analysis plans: 
 Original protocol (version 2.0, approved before the first site opened)   
 Final protocol (version 9.0)   
 Version control document (summary of changes)   
 Original statistical analysis plan (version 1.0)   
 Second and final statistical analysis plan (version 2.0, changes listed in section 1.6)  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Study Synopsis 
Title   
 
Paclitaxel assisted balloon Angioplasty of Venous stenosis in haEmodialysis access.   
Protocol Short Title  PAVE Trial 
Protocol Version number/ Date  Version 1.0 
Is the study a Pilot?  No 
Study Hypothesis  The hypothesis is that we will demonstrate efficacy of paclitaxel-coated balloons in 
improving outcomes after fistuloplasty of stenotic arteriovenous fistulae. 
Methodology  Double-blind multicentre randomised controlled trial 
Sponsor name  K  C  L  / GS  NHS F   
Chief Investigator  Dr Michael Robson 
REC number  15/LO/0638 
Condition under investigation  Arteriovenous fistulae used for haemodialysis in patients with end stage kidney disease. 
Purpose of clinical trial  RCT to assess the efficacy of additional paclitaxel-coated balloon fistuloplasty 
compared to plain balloon fistuloplasty only to preserve the patency of arteriovenous 
fistulae used for haemodialysis. 
Number of Patients  211  
Trial Design   Double-blind multicentre randomised controlled trial with variable follow up  
(minimum 1 year) 
Endpoints  The primary endpoint is time to end of target lesion primary patency (TLPP).   
Secondary endpoints: 
1.  Angiographically determined late lumen loss 
2. The rate of binary angiographic re-stenosis 
3. Time to end of access circuit primary patency  
4. Time to end of access circuit cumulative patency  
5. Procedural success       
6. Number of thrombosis events 
7. Adverse events      
8. Patient quality of life assessed by EQ-5D and POS-S Renal 
Inclusion Criteria  1. Patients (18 years or over) who have a native AVF in the arm that has been used for 
haemodialysis for at least 12 dialysis sessions 
2. An indication for a fistuloplasty as determined by the local clinical team 
3. The access circuit is free of synthetic graft material or stents  
4. A reduction of vessel d    50%  ,    
diameter of the outflow vein of at least 4 mm and less than the size of the largest 
available drug-coated balloon 
5. A     30%  plain balloon fistuloplasty 
Exclusion Criteria  1. Patient unable to give informed consent 
2. Patient unwilling or unable to comply with all study-related procedures 
3. Systemic or local (to the fistula) infection treated for less than 10 days prior to the 
study procedure 
4. Synchronous venous lesion (with a reduction of vessel diameter of  50% measured 
angiographically) in the same access circuit 
5. Location of stenosis beyond the thoracic inlet 
6. Thrombosed (failed) dialysis circuit at time of treatment  
7. Women who are breastfeeding, pregnant or are intending to become pregnant or men 
intending to father children within two years of study treatment 
8. Known hypersensitivity or contraindication to contrast medium which cannot be 
adequately premedicated 
9. Known hypersensitivity or contraindication to paclitaxel 
Statistical Methodology and 
Analysis 
 To test the superiority of the paclitaxel-coated balloon treatment group compared to 
placebo balloon in TLPP survival we will use Cox-Proportional Hazards regression, on 
an intention to treat basis.  
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Glossary of Terms and Abbreviations  
 
AE   Adverse Event   
AR   Adverse Reaction 
AVF   Arteriovenous fistula 
AVG   Arteriovenous graft 
Atm   Atmospheres (pressure) 
CI   Chief Investigator 
CRF   Case Report Form 
CRO   Contract Research Organisation 
DMC   Data Monitoring Committee 
EC   European Commission 
ISRCTN  International Standard Randomised Controlled Trial Number 
REC   Research Ethics Committee 
NHS R&D  National Health Service Research & Development   
PI   Principle Investigator 
RCT   Randomised Controlled Trial 
REC   Research Ethics Committee 
SAE   Serious Adverse Event 
SOP   Standard Operating Procedure  
SSA   Site Specific Assessment 
TLPP   Target Lesion primary patency 
TMG   Trial Management Group 




Device Name  Lutonix 035 Drug Coated Balloon PTA Catheter 
(Treatment) 
Ultraverse 035 PTA Dilatation Catheter (Placebo) 
Dorado PTA Dilatation Catheter (Plain balloon) 
Manufacturer Name   C.R Bard, Inc.  
Principle intended use   Angioplasty of stenosed blood vessels 
Is the device CE-marked and used within 
its purpose? 
 Yes  




Description and Maintenance and storage of device 
The balloons will be stored under routine conditions in the radiology department.  
No special measures or maintenance is needed.  
 
Are the devices registered on the DoH 
MIA Master Indemnity Scheme?   
   
Yes 
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1. Introduction 
 
1.1. Existing research  
 
Vascular access for haemodialysis 
The 2012 UK Renal Registry report (www.renalreg.com) found that 43.9% of patients with end-
stage kidney disease in the UK are on haemodialysis.  This equated to 365 patients per million 
population in the UK in 2011. This number has increased every year with an overall increase of 
3.6% from 2006 to 2011. In order to perform haemodialysis, reliable vascular access is 
essential.  It is universally agreed that the optimal form of access is a native arteriovenous 
fistula (AVF).  Although these are superior to synthetic arteriovenous grafts (AVGs), both AVFs 
and AVGs have a limited lifespan. Data from the Dialysis Outcomes and Practice Study 
(DOPPS) showed that in the US the one year patency for AVFs and AVGs is 68% and 49% 
respectively [1]. In Europe, one-year AVF survival was somewhat better at 83% but there is still 
a need for improvement. 
 
Problems with vascular access are an important cause of morbidity and mortality in 
haemodialysis patients.  In the US, it has been estimated that $1bn per year is spent on 
vascular access and its complications [2].  A recent survey in the UK found that haemodialysis 
patients occupy 320,000 bed days per year, with 30% of admissions related to vascular access 
(Renal Association vascular access audit, available at www.renal.org). Haemodialysis patients 
are at a greatly increased risk of invasive MRSA infection and this is largely related to the use of 
central venous catheters instead of AVFs or AVGs. When thrombosis or stenosis occurs in an 
AVF or AVG, a central venous catheter may be used for several months until an AVF or AVG is 
formed and is usable.  In some patients, a central venous catheter may become the only 
dialysis access that can be used.  Data from the US showed that the risk of invasive infection is 
increased 100 fold over the general population in haemodialysis patients, with 85% having 
catheters of invasive devices, and 90% requiring hospitalisation with a 17% mortality [3]. It is 
therefore imperative to preserve each AVF or AVG for as long as possible and to avoid the use 
of central venous catheters which lead to infective complications. 
 
The initial therapy for a stenosis in an AVF is radiological balloon dilatation or angioplasty.  
Monitoring of AVFs for reduced blood flow and pre-emptive angioplasty, or surgery, is 
performed in some centres.  Limited evidence supports this approach [4-6].  In contrast, the 
need for intervention when AVFs are clinically dysfunctional, with angioplasty or surgery, is 
established and will improve fistula function.  A major concern however is the longevity of this 
effect. One recent study addressed this and documented the outcomes after angioplasty in 159 
AVFs.  Angioplasty was performed due to AVF dysfunction in 96% of cases.  Primary assisted 
patency (AVF working regardless of repeat intervention) was 89% and 85% at 6 and 12 months 
respectively. However at 6, 12 and 24 months, the primary unassisted patency (AVF working 
with no repeat intervention) was 61%, 42% and 35% respectively [7].  These results are similar 
to our own local audit data, which showed 53% and 33% primary unassisted patency rate at 6 
and 12 months respectively. It is also similar, as regards event rate, to the prospective study of 
Tessitore et al (5).  In this study the primary outcome was AVF patency following angioplasty 
regardless of repeat intervention.  However, the restenosis rate following the initial angioplasty 
was reported to be 39% per year, with a median time to this event of 8 months. In addition to the 
need for better interventions to reduce restenosis rates, there is also a need to better 
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The biology of arteriovenous fistula dysfunction 
Neointimal hyperplasia leads to stenoses in the venous segments of AVFs, with the pathology 
characterised by an expansion of alpha smooth muscle actin positive myofibroblasts in the 
neointima [8].  In arteries, the contribution of bone-marrow derived cells to tissue repair depends 
on the nature and severity of injury [9].  The contribution of bone marrow cells to venous 
neointimal hyperplasia is not resolved and the data from animal studies are conflicting. Two 
studies using bone marrow transplantation with cells containing a green fluorescent protein 
(GFP) or -galactosidase reporter gene, have suggested a minimal contribution of bone-marrow 
derived cells in mouse and rat model respectively [10, 11].  However a further study employing 
a murine vein graft, has suggested that at least 20% of neointimal cells may be bone marrow 
derived [12].  GFP positive cells were detected by a more sensitive PCR method and these 
technical differences were suggested as a reason for discrepancies with other studies.   
 
In addition to these conflicting data on the origin of neointimal cells, it should be noted that none 
of the previous reports induced vein injury in way that would mirror the changes induced by 
angioplasty.  Instead, most have focussed on the development of primary stenosis in venous 
a   a a a ,     a a   a a  b  a  
in the flow characteristics of arterial blood to which it becomes exposed. Given the data from 
arterial studies, a contribution from bone marrow cells to the alpha smooth muscle actin 
producing cells in the hyperplastic neointima of a dysfunctional AV fistula is highly likely with the 
degree of trauma to the endothelium that would follow angioplasty. Angioplasty causes vessel 
wall damage with rupture of the junction between the intima and the media, with a burst of 
proliferation and repair. Much of our understanding of aggressive neointimal formation in this 
context comes from arterial studies [13], but similar pathology and an increase in proliferation 
has been shown in AVFs following venous angioplasty [14]. 
 
Paclitaxel exerts an antiproliferative effect by interfering with cell microtubule function [15].  
Systemic administration of paclitaxel after angioplasty in the rat carotid artery showed that a 
significant reduction in neointimal proliferation could be achieved at doses much lower than 
antineoplastic levels [16].  In rat and human cultured cell models, paclitaxel inhibited vascular 
smooth muscle cell migration and proliferation [16, 17], consistent with its effects in vivo.  As an 
alternative to systemic therapy, local drug delivery offers the advantages of allowing high local 
concentrations of drug at the treatment site while minimising systemic toxic effects.  Proof of this 
possibility was initially shown using paclitaxel-coated stents in pig coronary arteries [18].  
Recent advances in technology have allowed angioplasty balloons to be coated with paclitaxel. 
This allows local delivery of paclitaxel to the site of stenosis. A number of multi-centre 
randomised controlled trials in the coronary and peripheral arterial circulation have established 
the positive benefit of drug-coated balloons [19, 20]. A small pilot study has suggested efficacy 
in dialysis patients [21].  In this study, 40 patients with AVFs or AVGs were randomised to 
paclitaxel for the treatment of a clinically important stenosis. Unassisted primary patency of the 
treated lesion (defined angiographically as a binary readout of <50% stenosis) at 6 months was 
significantly better in the paclitaxel-coated balloon group (70 v 25%). This study may be 
criticised on a number of points. These include the use of an angiographic rather than a clinical 
endpoint, the lack of blinding and independent angiographic core lab analysis, the very small 
sample size originally intended to test non-inferiority only (with a wide 15% non-inferiority limit), 
and the short 6-month follow-up. In addition, a range of balloons was used in the control group 
for post-dilation after the paclitaxel-coated balloons, and these were not universally high 
pressure and non-compliant. This may have added variability to the outcome.   Furthermore, the 
inclusion of both AVFs (35%) and AVGs (65%) may have resulted in significant confounding, 
given the difference in survival rates associated to the two types of access. Despite these 
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limitations, the results suggested that a further study of efficacy was warranted, which is what 
we propose here.  This is the first large scale randomised controlled trial designed to test 
superiority of drug-coated balloons in haemodialysis access circuits. 
1.2. Risks and benefits  
The risks for patients taking part in this study are minimal.  The plain balloon fistuloplasty is 
standard of care and the additional intervention will be the use of a paclitaxel-coated balloon or 
control balloon following this initial dilatation. The paclitaxel-coated balloons that will be used 
are CE marked and there have been no safety concerns with their use.  In the specific context 
of haemodialysis AVFs, the pilot study performed did not raise any safety concerns [21]. 
 
1.3. Rationale for current study:  
The overriding aim of this study is preservation of vascular access for haemodialysis with a 
reduction in restenosis and the need for repeat fistuloplasties.  
 
Clinical Trial 
Our hypothesis is that we will demonstrate efficacy of paclitaxel-coated balloons in improving 
outcomes after fistuloplasty of stenotic AVFs.  As detailed in section 1.1, this hypothesis is 
supported by what is known of the effects of paclitaxel on the biology of neointimal formation, 
results in trials involving coronary and peripheral arteries, and a pilot study vascular access for 
haemodialysis. 
 
This need for repeat procedures following angioplasty is expensive and inconvenient for 
patients and is needed in around 60% of patients during the first year [7]. As detailed in our 
sample size calculation we predict that the use of paclitaxel coated balloons will lead to an 
avoidance of the need for repeat angioplasty. Repeat angioplasties will also have a negative 
effect on patient quality of life and a reduction in these will be a benefit in addition to the 
reduction in cost.  
 
Collection of patient samples 
This clinical trial offers a unique opportunity to collect patient samples alongside detailed and 
carefully collected clinical and angiographic data in the setting of a clinical trial.  This will form an 
important resource for future laboratory based studies on biomarkers and AVF outcomes.   
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2. Trial Objectives, Design and Statistics 
 
2.1. Trial objectives 
The purpose of this RCT is to assess the efficacy of additional paclitaxel-coated balloon 
fistuloplasty compared to plain balloon fistuloplasty only to preserve the patency of 




Time to end of target lesion primary patency   
This is defined as patency with no re-intervention to the area 5mm proximal within, and 5 mm 
distal to, the index treatment segment. Target lesion primary patency ends when any of the 
following occur: (a) re-intervention to the treatment segment; (b) thrombotic occlusion that 
includes the treatment segment; (c) surgical intervention that excludes the treatment segment 
from the access circuit; (d) abandonment of the AVF due to an inability to retreat the treatment 
segment.  
 
Referral for a repeat procedure will originate from the clinical team who are unaware of whether 
the patient received treatment with a paclitaxel-coated balloon or uncoated control balloon.   
 
In order to confirm there is a significant stenosis prior to fistulography, a duplex ultrasound is 
encouraged but is not mandatory. 
 
A different radiologist to the one performing the index procedure will perform repeat procedures 
when possible but it is not possible to guarantee this.  Therefore the radiologist performing the 
repeat procedure may have knowledge of whether the patient was treated with drug-coated 
balloon or placebo.  
 
In order to allow us to demonstrate that there is no bias in the final decision to proceed with the 
repeat intervention we will do the following:  In patients who have not yet reached the primary 
endpoint, any pre-procedure fistulograms prior to re-intervention or potential re-intervention will 
be sent to an independent angiographic laboratory for analysis. This will allow confirmation that 
a significant stenosis was found in all patients who received a repeat intervention, and not in the 
small number who underwent fistulography but not an intervention, regardless of which arm of 
the trial the patient is in. The specifications for this fistulogram are defined in section 4.5. 
 
Secondary Endpoints:  
 
1. Angiographically determined late lumen loss.   
This is the difference between the diameter of the treatment segment post-procedure and the 
diameter at 6 months as measured by an independent core laboratory. If a patient has a repeat 
procedure to the treatment segment before 6 months, then the pre-intervention images will be 
used for analysis and a fistulogram at 6 months will not be performed. 
 
2. The rate of angiographic binary re-stenosis. 
This is defined as the incidence of stenosis of at least 50% within the treated lesion at the 6 
month follow-up fistulogram. If a patient has a repeat procedure to the index lesion before 6 
months, then the pre-intervention images will be used for analysis and a fistulogram at 6 months 
will not be performed. 
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3. Time to end of access circuit primary patency  
The access circuit is defined as starting at the arterial anastomosis and ending at the cavoatrial 
junction.  Access circuit primary patency ends when any of the following occur: (a) access circuit 
thrombosis, (b) an intervention (either radiological or surgical) anywhere in the access circuit, or 
(c) the access circuit is abandoned due to an inability to treat any lesion. 
 
4. Time to end of access circuit cumulative patency  
Access circuit cumulative patency ends when the AVF is abandoned, regardless of radiological 
or surgical intervention, with or without a thrombosis event. Multiple/repetitive treatments for 
stenoses that restore patency are compatible with cumulative patency.  
 
5.   (    0%  completion fistulogram II, see section 4.4 
below) 
 
6. Number of thrombosis events 
 
7. Adverse events (e.g. fistula rupture, infection) 
 
8. Patient quality of life as assessed by the EuroQuol EQ-5D generic health survey, and the 
disease specific Patient (or Palliative care) Outcome Scale symptom score-renal (POS-S 
Renal) [22]. 
2.2 Trial design
The study design used to achieve this will be a double-blind multicentre randomised controlled 
trial.  We will recruit 211 patients over a two-year period. Patients will be randomized in a 1:1 
ratio.  Randomisation will be stratified for two variables. These will be firstly study centre and 
secondly, whether they have had a previous radiological intervention to the treatment area or 
not. Patients will be followed up for a minimum of one year, and all patients will continue in the 
study until the last patient has completed one year of follow up.  
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2.3 Trial schedule 
 
 
* Prior to randomisation, eligibility will be reviewed based on the radiological findings on both the pre-procedure fistulogram and completion fistulogram I 
**At each follow up assessment information to be checked or collected will include the following: target lesion primary patency, access circuit primary and cumulative patency, access circuit 
interventions, thrombosis events, patient medications, access circuit dysfunction, and adverse events. 
***Follow up will be for a minimum of 12 months and a maximum of 36 months. 
****Post-procedure study assessments occur every 3 months ± 1 month.
 Pre-
procedure 




































Patient registration and consent x 
  
             




             
Consideration of eligibility x 
 
             
Discussion and confirmation of potential 
eligibility with radiologist 
 x 
 
             




x x x           
Pre-procedure fistulogram *   x                    
Plain balloon fistuloplasty    x                  
Completion fistulogram I *    x                 
Randomisation     x                
Study treatment      x               
Completion fistulogram II       x              
Protocol fistulogram     x           
Follow up assessments  **  ***     x x x x x x x x x x x x 
Quality of life assessments  
(POS-S Renal and EQ-5D) 
x     x  x         
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2.4 Trial flowchart 
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2.5 Trial statistics 
Analysis of Primary Outcome: To test the superiority of the paclitaxel-coated balloon treatment group 
compared to placebo balloon in TLPP survival we will use Cox-Proportional Hazards regression, on an 
intention to treat basis. Primary analysis will be repeated using multivariate cox regression for the 
adjustment of the treatment effect size for the effect of known clinical covariates.  Patients with TLPP 
at the end of follow up will be considered censored, as will those 
who receive a renal transplant, switch to peritoneal dialysis or 
are lost to follow up before the study end.  Kaplan-Meier plots, 
hazard-ratio and its confidence interval will be used to describe 
the results.  
 
Analysis of Secondary Outcomes: Effects on secondary 
outcomes will be analysed using the same strategy for time-to-
event variables, and generalized linear models for binary and 
continuous outcome measures, adjusting for the effects of 
relevant covariates when appropriate. Continuous variables will 
be checked for normality, transformed if necessary or otherwise 
analysed using a Wilcoxon-signed-rank test for independent 
samples. 
 
Missing Values and Drop-outs: If necessary, multiple imputation 
will be used for the imputation of missing values in baseline variables and secondary outcomes.  
Patients lost to follow up will be compared to patients who reach complete follow up in baseline 
characteristics and adverse events to test whether drop-outs are random. 
 
Interim Analysis: Interim analysis of the primary outcome will be performed three times throughout the 
study, based on the cumulative number of failures of the treatment area, i.e. after 27, 54 and 81 
events, expected approximately at 9, 14 and 19 months of study under the null, and at months 11, 17, 
and 23 under the alternative. Group sequential stopping boundaries have been calculated using a 
Lan-de-M    (  O B -Fleming parameters), to allow early stopping for rejection 
of the null or the alternative hypotheses. Stopping in case of boundary crossing is non-binding.  
 
3.  Sample Size, Selection and Withdrawal of Subjects 
 
3.1 Sample size 
For the definition of the survival curve in the placebo balloon group, we assumed target lesion primary 
patency of 61%, 42%, and 35% at 6, 12 and 24 months respectively.  This was consistent with 
published results [7] and with our own audit data. A hazard ratio (HR) of 0.5 was chosen as the 
minimum clinically relevant effect size. Katsanos et al. [21] found a HR of 0.3 for TLPP at 6 months; 
however, the confidence interval was broad and the effect size is expected to be closer to the null 
when AVGs are excluded. Based on these assumptions, it is expected that the paclitaxel coated 
balloon group will show 78%, 65%, and 59% survival of TLPP at 6, 12 and 24 months respectively.  
Recruiting 211 patients, with variable follow up, a minimum follow up of 1 year, and three interim 
analyses, will provide 94% power to detect a statistically significant difference between the two groups 
in TLPP survival with 2-sided 5% type I error rate. It is expected that 108 patients will experience 
fistula failure during the follow up period. 
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The required sample size has been estimated assuming cumulative 10% drop-out in each treatment 
arm by the end of the study, and recruitment of 2 patients per month (ppm) during the first three 
months, 8 ppm up to 7 months, and 12 ppm onwards. The expected accrual duration will be 22 
months, and the maximum study duration (including follow-up) 34 months. 
3.2 Inclusion criteria  
 
1. Patients (18 years or over) who have a native AVF in the arm that has been used for haemodialysis 
for at least 12 dialysis sessions. 
 
2. An indication for a fistuloplasty as determined by the local clinical team 
 
3. The access circuit is free of synthetic graft material or stents 
 
4. A    a    50% a  a a a , a  a  a   
the outflow vein of at least 4 mm and less than the size of the largest available drug-coated balloon 
 
5. A a    30% a  plain balloon fistuloplasty 
 
 
3.3 Exclusion criteria  
 
1. Patient unable to give informed consent 
 
2. Patient unwilling or unable to comply with all study-related procedures 
 
3. Systemic or local (to the fistula) infection treated for less than 10 days prior to the study procedure 
 
4. Synchronous venous lesion, with a reduction of vessel diameter of  50% measured 
angiographically, in the same access circuit 
 
5. Location of stenosis beyond the thoracic inlet 
 
6. Thrombosed (failed) dialysis circuit at time of treatment  
 
7. Women who are breastfeeding, pregnant or are intending to become pregnant or men intending to 
father children, within two years of study treatment 
 
8. Known hypersensitivity or contraindication to contrast medium which cannot be adequately 
premedicated 
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3.4 Criteria for premature withdrawal  
Participants have the right to withdraw from the study at any time for any reason.   
Participants will be withdrawn from the study if any of the following occur: 
 Death of participant 
 Participant receives a transplant 
 Participant is changed from haemodialysis to peritoneal dialysis 
The PI also has the right to withdraw patients from the study in the event of inter-current illness, AEs, 
SAE ,  a , a a  a   other reasons, e.g. the participant is no longer 
being treated at a hospital included in the study. 
It is understood by all concerned that an excessive rate of withdrawals can render the study 
uninterpretable; therefore, unnecessary withdrawal of patients should be avoided.  Should a patient 
decide to withdraw from the study, all efforts will be made to report the reason for withdrawal as 
 a  .  Pa a     a   a    a    
whether they are still willing to provide study specific data and samples for scientific laboratory 
analysis according to the trial protocol. 
 
4.   Study Procedures 
 
4.1 Screening procedures  
Patients that may be eligible will be identified in a vascular access clinic and assessed by surgeons, 
specialist nurses and nephrologists.   
 
In order to confirm there is a significant stenosis prior to angiography, a duplex ultrasound is 
encouraged but is not mandatory. 
 
At least 24 hours after being given the patient information sheet and before entering the angiography 
room for the pre-procedure fistulogram, consent will be taken and eligibility criteria as listed above in 
section 3 will be assessed.  Inclusion criteria 1 and 2 will be confirmed and exclusion criteria 1-3 and 
6-9 will be assessed. 
 
The radiologist who will perform the pre-procedure fistulogram will be informed that the patient is 
potentially eligible for the study. 
 
4.2 The pre-procedure fistulogram 
This will be performed in a dedicated Interventional Radiology suite equipped with digital subtraction 
angiogram, image overlay/roadmap post processing capabilities and ability to capture still and video 
DICOM file data.   
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It will be performed through a sheath or cannula placed in the dialysis circuit according to the following 
specifications: 
   
1. All fistulograms performed as digital subtraction acquisitions at 3 frames per second 
 
2. The entire access circuit from anastamosis to central vein covered in up to 3 stages 
 
3. Medial epicondyle of humerus visible bony landmark on lower arm acquisition, 
acromioclavicular joint on upper arm and central acquisitions 
 
4. Measurement ruler in view 
 
5. Lower arm acquisition to include: 
i. Anteroposterior Projection of anastomosis 
ii. Oblique projection of anastomosis (specify oblique and craniocaudal angulation) 
 
6. On the acquisition that best demonstrates the target lesion, the following measurements 
are made: 
i. Proximal (close to anastomosis) reference vessel diameter 
ii. Minimum lumen diameter (MLD) 
iii. Distal reference vessel diameter 
 
The radiologist will assess inclusion criteria 3 and 4, and exclusion criteria 4 and 5, to decide if the 
patient remains eligible for the study.  
 
 
4.3 The plain balloon fistuloplasty procedure 
This will be performed in a dedicated Interventional Radiology suite equipped with digital subtraction 
angiogram, image overlay/roadmap post processing capabilities and ability to capture still and video 
DICOM file data, according to the following specifications: 
 
Prior to treatment 3000-5000 IU of heparin is administered. For all patients treatment has two 
components.  The first is fistuloplasty, performed with a dedicated high pressure balloon (Bard 
Dorado) ensuring the following criteria are met: 
1. Sized to nominal vein diameter  
2. Up to 24 Atm to ensure obliteration of the lesion waist  
3. Minimum duration of balloon inflation 1 minute.    
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Completion fistulogram I is performed after the plain balloon fistuloplasty to ensure adequate therapy 
according to the following specifications: 
 
1. All fistulograms performed as digital subtraction acquisitions at 3 frames per second 
2. Acquisition that demonstrates the target lesion matched as close as possible to the 
respective pre-procedure fistulogram acquisition 
 
3. Measurement ruler in view 
 
4. The following measurements are made: 
i. Proximal (close to anastomosis) reference vessel diameter 
ii. Minimum lumen diameter (MLD) 
iii. Distal reference vessel diameter 
 
The radiologist will assess completion fistulogram I and decide if the residual stenosis is  30% 
(inclusion criteria 5). If this is the case the patient will proceed to randomisation, but if not the patient 
will be excluded. 
 
4.4 Randomisation procedures  
Randomisation will take place via a web based randomisation service, hosted at the UKCRC 
registered clinical trials unit at KCL. Site staff will access the service via www.ctu.co.uk using a 
computer in the angiography room or an office nearby. It will be performed by the radiologist or their 
nominee. Each randomiser will have unique user access. Access will be provided by the CTU upon 
the authorisation of the trial manager, once the delegation of authority form has been completed and 
relevant documentation regarding the individuals has been collected. Nominees must not be clinicians 
or nurses who may decide to refer the patient for re-intervention. 
 
Patients will be randomized in a 1:1 ratio.  The two groups will be stratified by two variables. These will 
be firstly study centre and secondly, whether they have had a previous radiological intervention to the 
treatment area or not. Once randomised, email confirmations will be generated from the randomisation 
system and will be sent to relevant study staff in a blinded or unblinded format, depending on their role 
in the study.  
If it is not possible to use the randomisation system randomisation may occur using the toss of a coin 
in order to avoid losing the patient from the study. This should only be needed, if at all, in specific and 
rare situations such as the CTU server being inaccessible.  This will be performed by two people with 
heads denoting drug-coated balloon, and tails denoting placebo. The CTU must be informed of the 
coin randomisation as soon as possible. 
 
 
4.5 Study treatment 
In the intervention arm, the second component is insertion of a drug coated balloon (Bard Lutonix) of 
identical diameter and length to the high pressure balloon inflated to nominal pressure at the lesion 
location for a minimum of 1 minute duration.   
Instructions for use of the drug coated balloon are stringently adhered to ensure appropriate 
preparation and handling of the device.  
In the control arm, an identical procedure is followed, but using a placebo balloon that is not drug 
coated (Bard Ultraverse), of identical diameter and length to the high pressure balloon inflated to 
nominal pressure at the lesion location for a minimum of 1 minute duration. 
In both arms, image overlay/roadmap will be utilized to ensure that there is no geographical mismatch 
between the segments treated with the high and low pressure balloons. 
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Only the above 3 balloon types (Bard Dorado, Bard Lutonix and Bard Ultraverse) may be used in the 
study to ensure consistency and the above fistuloplasty procedure must be exactly followed. 
A completion fistulogram is again performed (completion fistulogram II) to confirm no angiographically 
visible effect after treatment with the drug-coated or placebo balloon, according to the following 
specifications: 
 
1. All fistulograms performed as digital subtraction acquisitions at 3 frames per second 
 
2. Acquisition that demonstrates the target lesion matched as close as possible to the respective 
pre-procedure fistulogram acquisition 
 
3. Measurement ruler in view 
 
4. The following measurements are made: 
i. Proximal (close to anastomosis) reference vessel diameter 
ii. Minimum lumen diameter (MLD) 
iii. Distal reference vessel diameter 
 
P a     a  a a    30%   a  II. 
 
The data file(s) containing the initial pre-procedure fistulogram, and completion fistulogram I and II will 
be sent to the lead study site with the patient’s name replaced by the trial ID, and with each of the 
above groups of images clearly identified. Completion fistulogram II will then be sent to the 
independent angiographic laboratory for analysis. 
 
4.6 Study assessments 
These will occur every 3 months ± 1 month. Follow up will be variable but for a minimum of 1 year and 
a maximum of 3 years. These will involve a clinical assessment to take place either face-to-face or via 
a telephone conversation. Any face-to-face meetings will usually coincide with dialysis to avoid 
additional patient travel.  
 
Data recorded for each study assessment will include the following: target lesion primary patency, 
access circuit primary and cumulative patency, access circuit interventions, thrombosis events, patient 
medications, access circuit dysfunction, and adverse events.  At the 6 month study assessment, the 
trial team will check if referral for re-intervention is being considered based on clinical concerns. If this 
is the case then a fistulogram plasty will be performed according to usual clinical practice and the 
patient will not undergo a protocol fistulogram.  
 
If there are no clinical concerns related to the fistula, then patients will be invited to undergo a protocol 
fistulogram.  Confirmation that there is no contraindication to this protocol fistulogram will be obtained 
from an appropriate doctor and documented.  
  
4.7 Radiology Assessments  
 
4.7.1 The 6 month protocol fistulogram 
This will take place within 2 weeks of the 6 month study assessment. 
 
If a patient has required a repeat fistuloplasty to the treatment area at or before 6 months then they 
will not undergo the 6 month protocol fistulogram. 
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All other patients will be invited to undergo a protocol fistulogram 6 months after the index procedure 
to acquire the data for the angiographic secondary endpoints 1 and 2 above. If a patient declines the 6 
month protocol fistulogram of does not have it for another reason, this will not be considered a 
protocol violation and the patient may continue in the study. 
 
The 6 month protocol fistulogram must be performed by a radiologist other than the one who 
performed the index procedure to ensure that they are blind to which trial arm the participant belongs. 
With forward planning this should be possible but if it is not then the protocol fistulogram should not be 
performed. 
 
A fistuloplasty will not be performed at the time of the 6 month protocol fistulogram unless an 
unsuspected stenosis is found and the radiologist believes that it would be unethical not to intervene.  
This will not be considered a protocol violation and a fistula intervention form must be completed. 
 
The 6 month protocol fistulogram will be performed in a dedicated Interventional Radiology suite 
equipped with digital subtraction angiogram, image overlay/roadmap post processing capabilities and 
ability to capture still and video DICOM file data.  It will be performed through a sheath or cannula 
placed in the dialysis circuit according to the following specifications: 
 
1. All fistulograms performed as digital subtraction acquisitions at 3 frames per second 
 
2. The entire access circuit from anastomosis to central veins covered in up to 3 stages 
 
3. Medial epicondyle of humerus visible bony landmark on lower arm acquisition, 
acromioclavicular joint on upper arm and central acquisitions 
 
4. Measurement ruler in view 
 
5. Lower arm acquisition to include: 
i. Anteroposterior Projection of anastomosis 
ii. Oblique projection of anastomosis (specify oblique and craniocaudal angulation) 
 
6. On the acquisition that best demonstrates the target lesion, the following measurements are 
made: 
i. Proximal (close to anastomosis) reference vessel diameter 
ii. Minimum lumen diameter (MLD) 
iii. Distal reference vessel diameter 
 
 
The 6 month protocol fistulogram will be considered to be exclusively trial data. The result of the 6 
month protocol fistulogram will not be made available (verbally or in writing) to the clinical team 
responsible for considering future referral of the patient to radiology. The images will also not be 
available on the local radiology system. The images will be sent to the lead site in order to be 
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4.7.2 Fistulograms performed for a clinical indication 
The follow applies only in patients who have not yet reached the primary endpoint of the trial. 
 
Pre-procedure fistulograms performed for a clinical indication will follow these specifications: 
1. All fistulograms performed as digital subtraction acquisitions at 3 frames per second 
2. The entire access circuit from anastomosis to central veins covered in up to 3 stages 
3. Medial epicondyle of humerus visible bony landmark on lower arm acquisition, acromioclavicular 
joint on upper arm and central acquisitions 
4. Measurement ruler in view 
5. Lower arm acquisition to include: 
i. Anteroposterior Projection of anastomosis 
ii. Oblique projection of anastomosis (specify oblique and craniocaudal angulation) 
6. On the acquisition that best demonstrates the target lesion, the following measurements are 
made: 
i. Proximal (close to anastomosis) reference vessel diameter 
ii. Minimum lumen diameter (MLD) 
iii. Distal reference vessel diameter 
 
The image file will be sent to the lead site in order to be forwarded to the independent core laboratory 
for analysis with the patient details replaced by the trial PIN. This will be sent regardless of whether 
the fistulogram is followed by a fistuloplasty. 
 
This will allow us to demonstrate that there is no bias in the final decision to proceed, or not, with the 
repeat intervention. 
 
4.8 End of Study Definition 
The clinical trial will end when 211 patients have been recruited and all patients have completed at 
least one year of follow up.  
 
The trial may be prematurely discontinued by the Sponsor, Funder, Chief Investigator or TSC on the 
basis of new safety information or for other reasons given by the DMC, TSC, REC, or from other 
sources. The trial may also be prematurely discontinued due to lack of recruitment or upon advice 
from the TSC who will advise on whether to continue or discontinue the study and make a 
recommendation to the sponsor.  If the trial is prematurely discontinued, active participants will be 
informed and no further participant data will be collected.  
 
5. Laboratories  
 
5.1 Laboratory tests 
There are no local laboratory tests that are required to provide data that directly relate to trial 
endpoints.   A 10 ml blood sample will be requested at the four timepoints stated in the trial schedule 
(2.3), and is to be sent to the local clinical laboratory for a full blood count and to check the C-reactive 




5.2 Core laboratory angiographic analysis  
The completion fistulogram II (taken after treatment with the drug coated balloon or placebo low 
pressure balloon) will be analysed in a core laboratory and compared with the pre-procedure 
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fistulogram performed routinely at 6 months (or the pre-procedure fistulogram taken prior to any re-
intervention at the treatment area if this is before 6 months). 
 
In addition, any pre-procedure fistulograms that are not followed by a re-intervention, and any pre-
procedure fistulograms that are performed after 6 months and are followed by a re-intervention, will be 
sent to the core laboratory for analysis. This is to allow an objective assessment of the decision to 
intervene or not after the pre-procedure fistulogram. 
 
5.3 Research sample Collection 
Blood (up to 90 ml) may be taken at each of the time points in the table of events in 2.3.  These will be 
sent to the research laboratory of the CI where the blood will be separated. Research blood samples 
should not be taken from patients who are known to be hepatitis B sAg, hepatitis C IgG or RNA, or 
HIV positive.  
 
DNA and RNA will be stored. Cells will be stored in aliquots in liquid nitrogen until thawed for analysis.  
Serum and/or plasma samples will be stored at -20 C  -80 C    . T , 
separation and storage will be according to Standard Operating Procedures.  
 
It will not be a considered a protocol violation if any of the blood samples are not taken, or are taken at 
different time points to those specified and patients may continue on the study.  
 
6. Assessment of Safety 
 
We have been informed by the MHRA that the PAVE protocol does not fall within the Clinical Trial 
Regulations and therefore is not a drug trial. In addition, the drug-coated balloon is a CE-marked 
medical device, so prior regulatory approval from the MHRA is not needed.   
 
Safety reporting will be in keeping with the requirements for research other than Clinical Trials of 
Investigational Medicinal Products.  
 
A Serious Adverse Event (SAE) is an untoward occurrence that:  
a) results in death 
b) is life-threatening  
c) requires non-elective hospitalisation or prolongation of existing hospitalisation  
d) results in persistent or significant disability or incapacity  
e) consists of a congenital anomaly or birth defect  
f) is otherwise considered medically significant by the investigator.  
  
All SAEs will be reported by the local investigators on the SAE form to the Chief Investigator, 
immediately they become aware and within 24 hours at most. A planned or non-elective hospital 
admission does not need to be reported as an SAE unless the PI decides it should be. 
 
Although it is not an SAE, any pregnancy or fathering of children that occurs within 2 years of the 
study treatment will be reported via the SAE system as below. 
 
Reports of SAEs will be reviewed by the CI within 24 hours to assess whether the event is related to 
the research procedure and unexpected (a SUSAR) and if so, it will be onward reported to the REC 
and DMC within 15 days, in the format prescribed by NRES and published on the website. 
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Since the study treatment is local and not systemic, non-serious adverse events will be defined as 
events that the PI considers are directly related to the vascular access that has been treated. These 
should be recorded throughout the trial and will be captured in the eCRF at each study assessment. 
 
7. Data Monitoring Committee    
 
The membership will be decided by the CI and approved by the NIHR. The DMC includes a statistician 
and two other independent experts.  They will receive a report of recruitment, serious and non-serious 
adverse events and a summary of accumulated clinical data from the trial statistician, and will meet in 
person or by telephone. They will report to the TSC who will usually meet in the two weeks following 
the DMC meeting. The DMC will meet at least annually during the study, approximately 2 weeks prior 
to the TSC. Additional meetings may take place at the time of interim analysis or in case of recruitment 
issues. The DMC is advisory to the TSC. The DMC charter will be drafted and agreed prior to 
recruitment. The Trial Statistician will prepare reports to the DMC. 
 
8. Trial Steering Committee    
 
The TSC will be convened in the post-award period. The membership will be decided by the CI and 
approved by the NIHR. The chair will be an independent expert.  Members will include the CI, a 
patient representative, and two other independent experts.  The TSC will meet at least annually during 
the study, approximately 2 weeks after the DMC. Additional meetings may take place at the time of 
interim analysis or in case of recruitment issues. The TSC is an executive committee. Terms of 
reference of the TSC will be agreed and documented prior to start of recruitment. The Trial Manager 
will prepare reports to the TSC. 
 
9. Ethics & Regulatory Approvals   
 
The trial will be conducted in compliance with the principles of the Declaration of Helsinki (1996), the 
principles of GCP and in accordance with all applicable regulatory requirements including but not 
limited to the Research Governance Framework.    
 
This protocol and related documents will be submitted for review to the London-Chelsea Research 
Ethics Committee (REC). 
 
The Chief Investigator will submit a final report at conclusion of the trial to the sponsor and the REC.  
 
Annual progress reports will be submitted to the main REC for the study. 
 
10. Data Handling 
 
All samples will be anonymised before laboratory analysis. No patient-related data will be held in 
research laboratories.   
 
During the study, any paper documents will be held in a locked filing cabinet in a locked office and 
retained for a minimum of 5 years following the end of the study.   
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C             CRF ,    K  
Clinical Trials Unit, KCL. The eCRF (InferMed MACRO) is GCP and FDA 21 CFR Part 11 compliant. 
Data entry staff at site will be provided with unique usernames and passwords to the system and will 
be trained in data entry by the trial manager. The trial manager will visit sites to review data on the 
system, raise discrepancies and confirm source data verification checks.  All requests for access to 
the data entry system must be authorised by the trial manager. All requests for data exports must be 
authorised by the trial statistician. The trial manager will work with the CI and the trial statistician to 
ensure data is checked and cleaned on an ongoing basis and will confirm all data checks have been 
completed before database lock. 
 
The investigators and the institutions will permit trial-related monitoring, audits, REC review, and 
regulatory inspections (where appropriate) by providing direct access to source data and other 
relevant documents (i.e.   ,   , -ray reports). Record keeping will 
be the responsibility of the investigators.   
 
11. Publication Policy 
 
It is intended that the results of the study will be reported and disseminated at international 
conferences and in peer-reviewed scientific journals. The chief investigator will review all 
presentations and publications arising from this study and decide authorship in accordance with 
accepted guidelines. 
 
12. Insurance / Indemnity 
 
T       K  C  L     -negligent harm.  In 
addition, the recruiting sites will have NHS indemnity. 
 
13. Financial Aspects 
 
The NIHR have supported the study through an EME programme grant award.  The fistuloplasty 
balloons are supplied by C.R. Bard, Inc. who have no other role in the design, running or analysis of 
the trial.  
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Study Synopsis 
Title   
 
Paclitaxel assisted balloon Angioplasty of Venous stenosis in haEmodialysis access.   
Protocol Short Title  PAVE Trial 
Protocol Version number/ Date  Version 9.0 08/11/2018 
Is the study a Pilot?  No 
Study Hypothesis  The hypothesis is that we will demonstrate efficacy of paclitaxel-coated balloons in 
improving outcomes after fistuloplasty of stenotic arteriovenous fistulae. 
Methodology  Double-blind multicentre randomised controlled trial 
Sponsor name  King’s College London / GSTT NHS Foundation Trust 
Chief Investigator  Dr Michael Robson 
REC number  15/LO/0638 
Condition under investigation  Arteriovenous fistulae used for haemodialysis in patients with end stage kidney disease. 
Purpose of clinical trial  RCT to assess the efficacy of additional paclitaxel-coated balloon fistuloplasty 
compared to plain balloon fistuloplasty only to preserve the patency of arteriovenous 
fistulae used for haemodialysis. 
Number of Patients  211  
Trial Design   Double-blind multicentre randomised controlled trial with variable follow up  
(minimum 1 year) 
Endpoints  The primary endpoint is time to end of target lesion primary patency (TLPP).   
Secondary endpoints: 
1.  Angiographically determined late lumen loss 
2. The rate of binary angiographic re-stenosis 
3. Time to end of access circuit primary patency  
4. Time to end of access circuit cumulative patency  
5. Procedural success       
6. Number of thrombosis events 
7. Total number of interventions 
8. Adverse events      
9. Patient quality of life assessed by EQ-5D and POS-S Renal 
Inclusion Criteria  1. Patients (18 years or over) who have a native AVF in the arm  
2. An indication for a fistuloplasty as determined by the local clinical team 
3. The access circuit is free of synthetic graft material or stents  
4. A reduction of vessel diameter of ≥ 50% measured angiographically, and a reference 
diameter of the outflow vein of at least 4 mm and less than the size of the largest 
available drug-coated balloon 
5. A residual stenosis of ≤ 30% after plain balloon fistuloplasty 
6. A treatment segment, containing one or more lesions, which can be treated with ≤120 
mm of a single drug-coated balloon 
 
Exclusion Criteria  1. Patient unable to give informed consent 
2. Patient unwilling or unable to comply with all study-related procedures 
3. Systemic or local (to the fistula) infection treated for less than 10 days prior to the 
study procedure. 
4. One or more lesions outside the treatment segment, with a reduction of vessel 
diameter of ³ 50% measured angiographically, in the same access circuit. The patient 
will also be excluded if any lesions outside the treatment segment are treated even if 
these are <50%. 
5. Location of stenosis central to the thoracic inlet 
6. Thrombosed (failed) access circuit at time of treatment  
7. Women who are breastfeeding, pregnant or are intending to become pregnant or men 
intending to father children within two years of study treatment 
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8. Known hypersensitivity or contraindication to contrast medium which cannot be 
adequately premedicated 
9. Known hypersensitivity or contraindication to paclitaxel 
 
Statistical Methodology and 
Analysis 
 To test the superiority of the paclitaxel-coated balloon treatment group compared to 
placebo balloon in TLPP survival we will use Cox-Proportional Hazards regression, on 
an intention to treat basis.  
 
 
Glossary of Terms and Abbreviations  
AE   Adverse Event   
AR   Adverse Reaction 
AVF   Arteriovenous fistula 
AVG   Arteriovenous graft 
Atm   Atmospheres (pressure) 
CI   Chief Investigator 
CRF   Case Report Form 
CRO   Contract Research Organisation 
DMC   Data Monitoring Committee 
EC   European Commission 
ISRCTN  International Standard Randomised Controlled Trial Number 
REC   Research Ethics Committee 
NHS R&D  National Health Service Research & Development   
PI   Principle Investigator 
PTA   Percutaneous Transluminal Angioplasty 
RCT   Randomised Controlled Trial 
REC   Research Ethics Committee 
PCB   Paclitaxel-coated balloon 
SAE   Serious Adverse Event 
SOP   Standard Operating Procedure  
Device Name  Lutonix 035 Drug Coated Balloon PTA Catheter 
(Treatment) 
Ultraverse 035 PTA Dilatation Catheter (Placebo) 
Dorado PTA Dilatation Catheter (Plain balloon) 
Manufacturer Name   C.R Bard, Inc.  
Principle intended use   Angioplasty of stenosed blood vessels 
Is the device CE-marked and used within 
its purpose? 
 Yes  




Description and Maintenance and storage of device 
The balloons will be stored under routine conditions in the radiology department.  
No special measures or maintenance is needed.  
 
Are the devices registered on the DoH 
MIA Master Indemnity Scheme?   
   
Yes 
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SSA   Site Specific Assessment 
TLPP   Target Lesion primary patency 
TMG   Trial Management Group 
TSC   Trial Steering Committee 
 
Disclaimer 
This project is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC 
and NIHR partnership. The views expressed in this publication are those of the author(s) and 
not necessarily those of the MRC, NIHR or the Department of Health and Social Care. 
1. Introduction 
 
1.1. Existing research  
 
Vascular access for haemodialysis 
The 2012 UK Renal Registry report (www.renalreg.com) found that 43.9% of patients with end-
stage kidney disease in the UK are on haemodialysis.  This equated to 365 patients per million 
population in the UK in 2011. This number has increased every year with an overall increase of 
3.6% from 2006 to 2011. In order to perform haemodialysis, reliable vascular access is 
essential.  It is universally agreed that the optimal form of access is a native arteriovenous 
fistula (AVF) are superior to synthetic arteriovenous grafts (AVGs) and tunnelled central venous 
catheters for haemodialysis access, AVFs and AVGs have  limited lifespans. Data from the 
Dialysis Outcomes and Practice Study (DOPPS) showed that in the US the one year patency for 
AVFs and AVGs is 68% and 49% respectively.  In Europe, one-year AVF survival was 
somewhat better at 83% but there is still a need for improvement [1].. 
 
Problems with vascular access are an important cause of morbidity and mortality in 
haemodialysis patients.  In the US, it has been estimated that $1bn per year is spent on 
vascular access and its complications [2].  A recent survey in the UK found that haemodialysis 
patients occupy 320,000 bed days per year, with 30% of admissions related to vascular access 
(Renal Association vascular access audit, available at www.renal.org). When thrombosis or 
stenosis occurs in an AVF or AVG, a central venous catheter may be used for several months 
until an AVF or AVG is formed and becomes usable. Data from the US has shown that the risk 
of invasive infection is increased 100 fold in haemodialysis patients compared to the general 
population. 85% of those diagnosed with an infection have an invasive device in situ. 90% of 
those diagnosed with an infection require hospitalisation and there is a 17% associated mortality 
[3]. It is therefore imperative to preserve each AVF or AVG for as long as possible and to 
minimise the use of central venous catheters. 
 
The initial therapy for a stenosis in an AVF is radiological fistuloplasty. A major concern however 
is the longevity of this effect. Turmel-Rodrigues et al reported the outcomes of interventional 
salvage of dysfunctional and thrombosed haemodialysis circuits [4]. There were 220 cases in 
the dysfunctional AVF group. The 6, 12, 24 month primary patency (AVF working with no repeat 
intervention) reported were 67%, 51% and 37% for forearm AVF and 57%, 35% and 24% for 
upper arm AVF respectively. Bountouris et al. reported the outcomes after 159 percutaneous 
transluminal angioplasties (PTAs) in AVFs. The primary patency at 6, 12 and 24 months were 
61%, 42% and 35% respectively [5].  Primary assisted patency (AVF working regardless of 
repeat intervention) was 89% and 85% at 6 and 12 months respectively. Although there have 
been some exceptions [6, 7], most other studies have reported similar primary patency rates of 
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around 40-50% at one year [8-10].    
 
The biology of arteriovenous fistula dysfunction 
In addition to the need for better interventions to reduce restenosis rates, there is also a need to 
better understand and identify the different types of response that occur following intervention. 
Neointimal hyperplasia leads to stenoses in the venous segments of AVFs, with the pathology 
characterised by an expansion of alpha smooth muscle actin positive myofibroblasts in the 
neointima [11].  In arteries, the contribution of bone-marrow derived cells to tissue repair 
depends on the nature and severity of injury [12].  The contribution of bone marrow cells to 
venous neointimal hyperplasia is not resolved and the data from animal studies are conflicting. 
Two studies using bone marrow transplantation with cells containing a green fluorescent protein 
(GFP) or β-galactosidase reporter gene, have suggested a minimal contribution of bone-marrow 
derived cells in mouse and rat model respectively [13, 14].  However a further study employing 
a murine vein graft, has suggested that at least 20% of neointimal cells may be bone marrow 
derived [15].  GFP positive cells were detected by a more sensitive PCR method and these 
technical differences were suggested as a reason for discrepancies with other studies.   
 
In addition to these conflicting data on the origin of neointimal cells, it should be noted that none 
of the previous reports induced vein injury in a way that mirrors the changes induced by 
angioplasty.  Instead, most have focussed on the development of primary stenosis in venous 
conduits undergoing arterialisation where endothelium is ‘traumatised’ or activated by changes 
in the flow characteristics of arterial blood to which it becomes exposed. Given the data from 
arterial studies, a contribution from bone marrow cells to the alpha smooth muscle actin 
producing cells in the hyperplastic neointima of a dysfunctional AV fistula is highly likely with the 
degree of trauma to the endothelium that would follow angioplasty. Angioplasty causes vessel 
wall damage with rupture of the junction between the intima and the media, with a burst of 
proliferation and repair. Much of our understanding of aggressive neointimal formation in this 
context comes from arterial studies [16], but similar pathology and an increase in proliferation 
has been shown in AVFs following venous angioplasty [17]. 
 
Paclitaxel exerts an antiproliferative effect by interfering with cell microtubule function [18].  
Systemic administration of paclitaxel after angioplasty in the rat carotid artery showed that a 
significant reduction in neointimal proliferation could be achieved at doses much lower than 
antineoplastic levels [19].  In rat and human cultured cell models, paclitaxel inhibited vascular 
smooth muscle cell migration and proliferation [19, 20], consistent with its effects in vivo.  As an 
alternative to systemic therapy, local drug delivery offers the advantages of allowing high local 
concentrations of drug at the treatment site while minimising systemic toxic effects.  Proof of this 
possibility was initially shown using paclitaxel-coated stents in pig coronary arteries [21].  
Recent advances in technology have allowed angioplasty balloons to be coated with paclitaxel. 
This allows local delivery of paclitaxel to the site of stenosis. A number of multi-centre 
randomised controlled trials in the coronary and peripheral arterial circulation have established 
the positive benefit of drug-coated balloons (DCBs) [22, 23].  A small pilot study has suggested 
efficacy in dialysis patients [24, 25].  In this study, 40 patients with dysfunctional AVFs or AVGs 
were randomised to receive either DCB or Plain Balloon Angioplasty (PBA). Primary unassisted 
patency (defined angiographically as a binary readout of <50% stenosis) in the DCB group was 
significantly better than the PBA group at 6 (70% v 25%) and 12 months (35% v 5%, p<0.001) 
respectively. This study may be criticised on a number of points. These include the use of an 
angiographic rather than a clinical endpoint, the lack of blinding and independent angiographic 
core lab analysis and the very small sample size originally intended to test non-inferiority only 
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(with a wide 15% non-inferiority limit). In addition, a range of balloons was used in the control 
group for post-dilation after the paclitaxel-coated balloons, and these were not universally high 
pressure and non-compliant. This may have added variability to the outcome.   Furthermore, the 
inclusion of both AVFs (35%) and AVGs (65%) may have resulted in significant confounding, 
given the difference in survival rates associated to the two types of access. Despite these 
limitations, the results suggested that a further study of efficacy was warranted, which is what 
we propose here.   
The PAVE trial is the first large scale randomised controlled trial designed to test superiority of 
DCBs in native haemodialysis access circuits. Further, the impact on patient quality of life will be 
performed.   
1.2. Risks and benefits  
The risks for patients taking part in this study are minimal.  The plain balloon fistuloplasty is 
standard of care and the additional intervention will be the use of a paclitaxel-coated balloon or 
control balloon following this initial dilatation. The paclitaxel-coated balloons that will be used 
are CE marked and there have been no safety concerns with their use.  In the specific context 
of haemodialysis AVFs, the pilot study performed did not raise any safety concerns [24]. 
 
1.3. Rationale for current study:  
The overriding aim of this study is preservation of vascular access for haemodialysis with a 
reduction in restenosis and the need for repeat fistuloplasties.  
 
Clinical Trial 
Our hypothesis is that we will demonstrate efficacy of paclitaxel-coated balloons in improving 
outcomes after fistuloplasty of stenotic AVFs.  As detailed in section 1.1, this hypothesis is 
supported by what is known of the effects of paclitaxel on the biology of neointimal formation, 
results in trials involving coronary and peripheral arteries, and a pilot study vascular access for 
haemodialysis. 
 
This need for repeat procedures following angioplasty is expensive and inconvenient for 
patients and is needed in around 60% of patients during the first year [5]. As detailed in our 
sample size calculation we predict that the use of paclitaxel coated balloons will lead to an 
avoidance of the need for repeat angioplasty. Repeat angioplasties will also have a negative 
effect on patient quality of life and a reduction in these will be a benefit in addition to the 
reduction in cost.  
 
Collection of patient samples 
Patient blood samples will also be collected within the setting of the clinical trial. This will form 
an important resource for future laboratory based studies on biomarkers and AVF outcomes.  
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2. Trial Objectives, Design and Statistics 
 
2.1. Trial objectives 
The purpose of this RCT is to compare the efficacy of additional paclitaxel-coated balloon 
fistuloplasty versus plain balloon fistuloplasty only to preserve the patency of arteriovenous 




Time to end of target lesion primary patency   
This is defined as patency with no re-intervention to the area 5mm proximal to, within, and 5 mm 
distal to, the index treatment segment. Target lesion primary patency ends when any of the 
following occur: (a) clinically driven re-intervention to the treatment segment; (b) thrombotic 
occlusion that includes the treatment segment; (c) surgical intervention that excludes the 
treatment segment from the access circuit; (d) abandonment of the AVF due to an inability to 
retreat the treatment segment.  
 
In order to confirm there is a significant stenosis prior to fistuloplasty, Duplex ultrasound is 
encouraged but is not mandatory. 
 
After the study treatment, occasionally there may be recoil or rupture necessitating further 
balloon angioplasty or stent placement. Providing further angioplasty and/or stent placement 
achieves a residual stenosis of less than 30%, these patients will remain in the study. 
 
Referral for a repeat procedure will originate from the clinical team who are unaware of whether 
the patient received treatment with a paclitaxel-coated balloon or uncoated control balloon.   
 
A different radiologist to the one performing the index procedure will perform repeat procedures 
when possible but it is not possible to guarantee this.  Therefore the radiologist performing the 
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repeat procedure may have knowledge of whether the patient was treated with drug-coated 
balloon or placebo.  
 
In order to ensure that there is no bias in the final decision to proceed with the repeat 
intervention in patients who have not yet reached the primary endpoint, pre-procedure 
fistulograms prior to potential re-intervention will undergo independent analysis. This will allow 
confirmation that a significant stenosis was found in all patients who received a repeat 
intervention.  
 
Secondary Endpoints:  
1. Angiographically determined late lumen loss.   
This is the difference between the diameter of the treatment segment post-procedure and the 
diameter at 6 months as measured by an independent core laboratory. If a patient has a repeat 
procedure to the treatment segment before 6 months, then the pre-intervention images will be 
used for analysis and a fistulogram at 6 months will not be performed. 
 
2. The rate of angiographic binary re-stenosis. 
This is defined as the incidence of stenosis of at least 50% within the treated lesion at the 6 
month follow-up fistulogram. If a patient has a repeat procedure to the index lesion before 6 
months, then the pre-intervention images will be used for analysis and a fistulogram at 6 months 
will not be performed. 
 
3. Time to end of access circuit primary patency  
The access circuit is defined as starting at the arterial anastomosis and ending at the cavoatrial 
junction.  Access circuit primary patency ends when any of the following occur: (a) access circuit 
thrombosis, (b) an intervention (either radiological or surgical) anywhere in the access circuit, or 
(c) the access circuit is abandoned due to an inability to treat any lesion. 
 
4. Time to end of access circuit cumulative patency  
Access circuit cumulative patency ends when the AVF is abandoned, regardless of radiological 
or surgical intervention, with or without a thrombosis event. Multiple/repetitive treatments for 
stenoses that restore patency are compatible with cumulative patency.  
 
5. Procedural success (residual stenosis ≤ 30% on completion fistulogram II, see section 4.4 
below) 
 
6. Number of thrombosis events 
 
7. Total number of interventions 
 
8. Adverse events (e.g. fistula rupture, infection) 
 
9. Patient quality of life as assessed by the EuroQol EQ-5D generic health survey, and the 
disease specific Patient (or Palliative care) Outcome Scale symptom score-renal (POS-S 
Renal) [26]. 
2.2 Trial design
The study design used to achieve this will be a double-blind multicentre randomised controlled 
trial.  We will recruit 211 patients over a three-year period. Patients will be followed up for a 
minimum of one year, and all patients will continue in the study until the last patient has 
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completed one year of follow up.  
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2.3 Trial schedule 
 
* Prior to randomisation, eligibility will be reviewed based on the radiological findings on both the pre-procedure fistulogram and completion fistulogram I 
**At each follow up assessment information to be checked or collected will include the following: target lesion primary patency, access circuit primary and cumulative patency, access circuit 
interventions, thrombosis events, patient medications, access circuit dysfunction, and adverse events 
***Follow up will be for a minimum of 12 months and a maximum of 48 months 
****Post-procedure study assessments occur every 3 months ± 1 month; Day 1-3 blood sample to be taken at next dialysis session after procedure, if this falls on a weekend then blood to be taken 
at the next dialysis session after this 
****Failure to complete the Quality of life assessments will not be deemed a protocol violation 
*****Bloods may also be collected pre and 1-3 days post the protocol fistulogram at Guy’s and St Thomas’ only 
 Pre-
procedure 









































Patient registration and consent x 
  
                




                
Consideration of eligibility x 
 
                
Discussion and confirmation of potential 
eligibility with radiologist 
 x 
 
                




x x               
Pre-procedure fistulogram *   x                       
Plain balloon fistuloplasty    x                     
Completion fistulogram I *    x                    
Randomisation     X                   
Study treatment      x                  
Completion fistulogram II       x                 
Protocol fistulogram     x              
Follow up assessments  **  ***     x x x x x x x x x x x x x x x 
Quality of life assessments **** 
(POS-S Renal and EQ-5D) 
x     x  x            
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2.4 Trial flowchart 
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2.5 Trial statistics 
Analysis of Primary Outcome: To test the superiority of the paclitaxel-coated balloon treatment group 
compared to placebo balloon in TLPP survival we will use Cox-Proportional Hazards regression, on an 
intention to treat basis. Primary analysis will be repeated using multivariate cox regression for the 
adjustment of the treatment effect size for the effect of known clinical covariates.  Patients with TLPP 
at the end of follow up will be considered censored, as will those 
who receive a renal transplant, switch to peritoneal dialysis or 
are lost to follow up before the study end.  Kaplan-Meier plots, 
hazard-ratio and its confidence interval will be used to describe 
the results.  
 
Analysis of Secondary Outcomes: Effects on secondary 
outcomes will be analysed using the same strategy for time-to-
event variables, and generalized linear models for binary and 
continuous outcome measures, adjusting for the effects of 
relevant covariates when appropriate. Continuous variables will 
be checked for normality, transformed if necessary or otherwise 
analysed using a Wilcoxon-signed-rank test for independent 
samples. 
 
Missing Values and Drop-outs: If necessary, multiple imputation 
will be used for the imputation of missing values in baseline variables and secondary outcomes.  
Patients lost to follow up will be compared to patients who reach complete follow up in baseline 
characteristics and adverse events to test whether drop-outs are random. 
 
Interim Analysis: Interim analysis of the primary outcome will be performed three times throughout the 
study, based on the cumulative number of failures of the treatment area, i.e. after 27, 54 and 81 
events, expected approximately at 9, 14 and 19 months of study under the null, and at months 11, 17, 
and 23 under the alternative. Group sequential stopping boundaries have been calculated using a 
Lan-de-Mets spending function (with O’Brian-Fleming parameters), to allow early stopping for rejection 
of the null or the alternative hypotheses. Stopping in case of boundary crossing is non-binding.  
 
3.  Sample Size, Selection and Withdrawal of Subjects 
 
3.1 Sample size 
For the definition of the survival curve in the placebo balloon group, we assumed target lesion primary 
patency of 61%, 42%, and 35% at 6, 12 and 24 months respectively.  This was consistent with 
published results [7] and with our own audit data. A hazard ratio (HR) of 0.5 was chosen as the 
minimum clinically relevant effect size. Katsanos et al. [21] found a HR of 0.3 for TLPP at 6 months; 
however, the confidence interval was broad and the effect size is expected to be closer to the null 
when AVGs are excluded. Based on these assumptions, it is expected that the paclitaxel coated 
balloon group will show 78%, 65%, and 59% survival of TLPP at 6, 12 and 24 months respectively.  
Recruiting 211 patients, with variable follow up, a minimum follow up of 1 year, and three interim 
analyses, will provide 94% power to detect a statistically significant difference between the two groups 
in TLPP survival with 2-sided 5% type I error rate. It is expected that 108 patients will experience 
fistula failure during the follow up period. 
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The required sample size has been estimated assuming cumulative 10% drop-out in each treatment 
arm by the end of the study, and recruitment of 2 patients per month (ppm) during the first three 
months, 8 ppm up to 7 months, and 12 ppm onwards. The expected accrual duration will be 36 
months, and the maximum study duration (including follow-up) 50 months. 
3.2 Inclusion criteria  
 
1. Patients (18 years or over) who have a native AVF in the arm  
 
2. An indication for a fistuloplasty as determined by the local clinical team 
 
3. The access circuit is free of synthetic graft material or stents 
 
4. A reduction of vessel diameter of ≥ 50% measured angiographically, and a reference diameter of 
the outflow vein of at least 4 mm and less than the size of the largest available drug-coated balloon 
 
5. A residual stenosis ≤ 30% after plain balloon fistuloplasty 
 
6.  A treatment segment, containing one or more lesions, which can be treated with ≤120 mm of a 
single drug-coated balloon. 
 
 
3.3 Exclusion criteria  
 
1. Patient unable to give informed consent 
 
2. Patient unwilling or unable to comply with all study-related procedures 
 
3. Systemic or local (to the fistula) infection treated for less than 10 days prior to the study procedure 
 
4. One or more lesions outside the treatment segment, with a reduction of vessel diameter of ³ 50% 
measured angiographically, in the same access circuit. The patient will also be excluded if any 
lesions outside the treatment segment are treated even if these are <50% 
 
5. Location of stenosis central to the thoracic inlet 
 
6. Thrombosed (failed) access circuit at time of treatment  
 
7. Women who are breastfeeding, pregnant or are intending to become pregnant or men intending to 
father children, within two years of study treatment 
 
8. Known hypersensitivity or contraindication to contrast medium which cannot be adequately 
premedicated 
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3.4 Criteria for withdrawal  
Participants have the right to withdraw from the study at any time for any reason.   
Participants will be withdrawn from the study if any of the following occur: 
• Death of participant 
• Participant receives a transplant 
• Participant is changed from haemodialysis to peritoneal dialysis 
• The fistula is ligated, abandoned, or thrombosed and not salvageable  
The PI also has the right to withdraw patients from the study in the event of inter-current illness, AEs, 
SAE’s, protocol violations, administrative reasons or other reasons, e.g. the participant is no longer 
being treated at a hospital included in the study. 
It is understood by all concerned that an excessive rate of withdrawals can render the study 
uninterpretable; therefore, unnecessary withdrawal of patients should be avoided.  Should a patient 
decide to withdraw from the study, all efforts will be made to report the reason for withdrawal as 
thoroughly as possible.  Participants who wish to withdraw from ‘treatment’ will be asked to confirm 
whether they are still willing to provide study specific data and samples for scientific laboratory 
analysis according to the trial protocol. 
 
4.   Study Procedures 
 
4.1 Screening procedures  
Patients that may be eligible will be identified in a vascular access clinic and assessed by surgeons, 
specialist nurses and nephrologists.   
 
In order to confirm there is a significant stenosis prior to angiography, a duplex ultrasound is 
encouraged but is not mandatory. 
 
Consent will be taken after the patient has had sufficient time to read the information sheet, consider 
the trial and ask questions.  
 
Eligibility criteria as listed above in section 3 will be assessed.   
 
If the patient remains potentially eligible for the study, the radiologist who will perform the pre-
procedure fistulogram will be informed. 
 
 
4.2 The pre-procedure fistulogram 
 
This will be take place immediately prior to the plain balloon fistuloplasty. 
 
This will be performed in a dedicated Interventional Radiology suite equipped with digital subtraction 
angiogram, image overlay/roadmap post processing capabilities and ability to capture still and video 
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DICOM file data.   
 
It will be performed through a sheath or cannula placed in the dialysis circuit according to the following 
specifications: 
   
1. All fistulograms performed as digital subtraction acquisitions at 3 frames per second (fps) if 
possible.  If the equipment will not allow 3 fps then 2 fps is acceptable. 
 
2. The entire access circuit from anastomosis to central vein covered in up to 3 stages 
 
3. Medial epicondyle of humerus visible bony landmark on lower arm acquisition, 
acromioclavicular joint on upper arm and central acquisitions 
 
4. Measurement ruler in view 
 
5. Lower arm acquisition to include: 
i. Anteroposterior Projection of anastomosis 
ii. Oblique projection of anastomosis (specify oblique and craniocaudal angulation) 
 
6. On the acquisition that best demonstrates the target lesion, the following measurements 
are made: 
i. Peripheral (close to anastomosis) reference vessel diameter 
ii. Minimum lumen diameter (MLD) 
iii. Central reference vessel diameter 
 
The radiologist will assess all inclusion and exclusion criteria, to decide if the patient remains eligible 
for the study.  
 
 
4.3 The plain balloon fistuloplasty procedure 
This is performed as standard of care.  Prior to treatment 3000-5000 IU of heparin is administered. For 
all patients treatment has two components. The fistuloplasty procedure is performed with a dedicated 
plain balloon (Bard Dorado).  Only if the anatomy of the lesion precludes the use of the Bard Dorado, 
then an alternative high pressure balloon may be used, providing it has a rated burst pressure of >18 
Atm.  The following criteria will be met: 
1. Sized to nominal vein diameter  
2. Up to 24 Atm to ensure obliteration of the lesion waist  
3. Minimum duration of balloon inflation 1 minute.    
 
Completion fistulogram I is performed after the plain balloon fistuloplasty to ensure adequate therapy 
according to the following specifications: 
 
1. All fistulograms performed as digital subtraction acquisitions at 3 frames per second (fps) if 
possible.  If the equipment will not allow 3 fps then 2 fps is acceptable. 
 
2. Acquisition that demonstrates the target lesion matched as close as possible to the 
respective pre-procedure fistulogram acquisition 
 
3. Measurement ruler in view 
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4. A core laboratory will make the following measurements at a later stage (these are not 
made by the radiologist performing the procedure) 
i. Peripheral (close to anastomosis) reference vessel diameter 
ii. Minimum lumen diameter (MLD) 
iii. Central reference vessel diameter 
The radiologist will assess all inclusion and exclusion criteria to decide if the patient remains eligible 
for the study.  
 
4.4 Randomisation procedures  
Randomisation will be at the level of the individual participants, minimising on radiologist performing 
the study procedure, whether the participant is currently on haemodialysis or not, and whether the 
participant has had a previous radiological intervention in the access circuit or not.  This is performed 
with an 80% probability of allocating to the arm which reduces the imbalance.  The allocation 
sequence will be generated dynamically.  This way, the next allocation will only be generated and 
become known upon actioning a request from the study site staff. 
 
Minimisation will be implemented using an independent web-based randomisation system hosted at 
the UKCRC registered clinical trials unit at KCL.  Site staff will access the service via www.ctu.co.uk 
using a computer in the angiography room or an office nearby. It will be performed by the radiologist or 
their nominee, who will log into the system, enter the participant ID number, initials, date of birth, 
recruiting radiologist, whether the participant is currently on haemodialysis or not, and whether the 
participant has had a previous radiological intervention in the access circuit or not.  Nominees must 
not be clinicians or nurses who may decide to refer the patient for re-intervention.  Each randomiser 
will have unique user access, provided by the CTU upon the authorisation of the trial manager, once 
the delegation of authority form has been completed.  
Once randomised, the system will automatically generate a confirmation email, which will be sent to 
relevant study staff in a blinded or unblinded format, depending on their role in the study.  
 
If it is not possible to use the randomisation system, randomisation may occur using the toss of a coin 
in order to avoid losing the patient from the study. This should only be needed, if at all, in specific and 
rare situations such as the CTU server being inaccessible.  This will be performed by two people with 
heads denoting drug-coated balloon, and tails denoting placebo. The CTU must be informed of the 
coin randomisation as soon as possible. 
 
 
4.5 Study treatment 
In the intervention arm, the second component is insertion of a single drug-coated balloon (Bard 
Lutonix).   
 
If a single plain balloon was inflated at one location, the drug-coated balloon must be of identical 
diameter to the plain balloon and a minimum of 1 cm longer than the plain balloon (5 mm at either 
end). 
 
In some cases more than one plain balloon may be used, or the same balloon may be inflated at 
different locations (eg to treat tandem lesions). In these cases, the drug-coated balloon must be of 
identical diameter to the largest diameter plain balloon used. The length of the drug-coated balloon 
must be a minimum of 1cm longer (5mm either end) than the entire segment of vein that has been in 
contact with plain balloon. 
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The drug-coated balloon will be inflated to nominal pressure at the lesion location for a minimum of 1 
minute duration.   
Instructions for use of the drug coated balloon are stringently adhered to ensure appropriate 
preparation and handling of the device.  
In the control arm, an identical procedure is followed, but using a single placebo balloon that is not 
drug coated (Bard Ultraverse).   
In both arms, image overlay/roadmap will be utilized to ensure that there is no geographical mismatch 
between the segments treated with the high and low-pressure balloons. 
 
A completion fistulogram is performed (completion fistulogram II) to confirm no angiographically visible 
effect after treatment with the drug-coated or placebo balloon, according to the same specifications as 
fistulogram I in section 4.3.  Procedural success is defined as a residual stenosis ≤ 30% on completion 
fistulogram II. 
   
The data file(s) containing the initial pre-procedure fistulogram, and completion fistulogram I and II will 
be sent to the lead study site with the patient’s name replaced by the trial ID, and with each of the 
above groups of images clearly identified. Completion fistulogram II will then be sent to the 
independent angiographic laboratory for analysis. 
 
4.6 Study assessments 
These will occur every 3 months ± 1 month. Follow up will be variable but for a minimum of 1 year and 
will continue for each patient while the study remains open. It is expected that the study will remain 
open for 4 years. These will involve a clinical assessment to take place either face-to-face or via a 
telephone conversation. Any face-to-face meetings will usually coincide with dialysis to avoid 
additional patient travel.  
 
Data recorded for each study assessment will include the following: target lesion primary patency, 
access circuit primary and cumulative patency, access circuit interventions, patient medications, and 
adverse events.   
 
At the 6-month study assessment, the trial team will check if referral for re-intervention is being 
considered based on clinical concerns.  
 
The decision to perform a protocol fistulogram or not to, will be confirmed with the PI after discussion 
with relevant clinical colleagues, and a consideration of the points discussed in 4.7.1. 
 
  
4.7 Radiology Assessments  
 
4.7.1 The 6 month protocol fistulogram 
 
Patients may be reimbursed for travel costs. 
 
The protocol fistulogram will take place within 6 weeks of the 6 month study assessment if no clinical 
concerns are identified. 
 
If clinical concerns are identified, then the protocol fistulogram may be delayed while the fistula is 
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assessed.  If the outcome of this assessment is that an angiogram or re-intervention is not indicated, 
the patient may then have a protocol fistulogram scheduled.  This must be no later than 9 months after 
the study intervention and treatment. 
 
If the outcome of this assessment is that an angiogram or re-intervention is indicated, then a 
fistulogram ±plasty will be performed according to usual clinical practice and the patient will not 
undergo a protocol fistulogram.   
  
If a patient has required a repeat fistuloplasty to the treatment segment at or before 6 months then 
they will not undergo the 6 month protocol fistulogram.   
 
If a patient declines the 6 month protocol fistulogram or does not have it for another reason, this will 
not be considered a protocol violation and the patient may continue in the study. 
 
The 6 month protocol fistulogram must be performed by a radiologist other than the one who 
performed the index procedure to ensure that they are blind to which trial arm the participant belongs. 
With forward planning this should be possible but if it is not then the protocol fistulogram should not be 
performed. 
 
The 6 month protocol fistulogram will be a diagnostic study only unless an unsuspected stenosis is 
found and the radiologist believes that it would be unethical not to intervene.  This will not be 
considered a protocol violation and a fistula intervention form will need to be completed. The 6 month 
protocol fistulogram will follow the same specifications as the pre-procedure fistulogram in section 4.2. 
 
The 6 month protocol fistulogram will be considered to be exclusively trial data. The result of the 6 
month protocol fistulogram will not be made available (verbally or in writing) to the clinical team 
responsible for considering future referral of the patient for an intervention. The images will also not be 
available on the local radiology system. The images will be sent to the lead site in order to be 
forwarded to the independent core laboratory with the patient’s name replaced by the trial ID.   
 
4.7.2 Fistulograms performed for a clinical indication 
In patients who have not yet reached the primary endpoint of the trial, pre-procedure fistulograms will 
follow the same specifications as the pre-procedure fistulogram specifications in section 4.2. The 
image file will be sent to the lead site with the patient details replaced by the trial PIN.  This will be 
sent regardless of whether or not the fistulogram is followed by a fistuloplasty.  
 
In patients who undergo an intervention, before 6 months, to the treatment segment, the pre-
procedure fistulogram will be used (by the independent core laboratory) in place of the 6 month 
protocol fistulogram for analysis of the angiographic secondary endpoints. 
 
4.8 End of Study Definition 
The clinical trial will end when 211 patients have been recruited and all patients have completed at 
least one year of follow up.  
 
The trial may be prematurely discontinued by the Sponsor, Funder, Chief Investigator or TSC on the 
basis of new safety information or for other reasons given by the DMC, TSC, REC. The trial may also 
be prematurely discontinued due to lack of recruitment or upon advice from the TSC who will advise 
on whether to continue or discontinue the study and make a recommendation to the sponsor.  If the 
trial is prematurely discontinued, active participants will be informed and no further participant data will 
be collected.  
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5. Laboratories  
 
5.1 Laboratory tests 
There are no local laboratory tests that are required to provide data that directly relate to trial 
endpoints.   A 10 ml blood sample will be requested at the three timepoints stated in the trial schedule 
(2.3), and is to be sent to the local clinical laboratory for a full blood count and to check the C-reactive 
protein level.  If patients decline some or all of these samples, it will not be considered a protocol 
violation. 
 
Blood (up to 90 ml) may be taken at each of the time points in the Trial Schedule in 2.3.  These will be 
sent to the research laboratory of the CI where the blood will be separated. Research blood samples 
should not be taken from patients who are known to be hepatitis B sAg, hepatitis C IgG/ RNA, or HIV 
positive. DNA and RNA will be stored. Cells will be stored in aliquots in liquid nitrogen until thawed for 
analysis.  Serum and/or plasma samples will be stored at -20’C or -80’C until thawed for analysis. 
Transport, separation and storage will be according to Standard Operating Procedures.  It will not be a 
considered a protocol violation if any of the blood samples are not taken, or are taken at different time 
points to those specified and patients may continue on the study.  
 
If a patient is enrolled but not randomised, the patient will not continue in the clinical trial. However 
blood samples may continue to be taken for laboratory research (at the same time points as for 
patients remaining in the trial).  Clinical data may also be recorded though this may not be on the 
eCRF system. 
 
5.2 Independent Core Lab Analysis 
The completion fistulogram II (taken after treatment with the DCB or placebo low pressure balloon) will 
be compared with the protocol 6 month fistulogram or with the pre-procedure fistulogram taken prior to 
a clinically driven re-intervention at the treatment segment if this is before 6 months. These will be 
analysed by an Independent Core Lab for the angiographic secondary endpoints.   
 
In addition, in patients who have not yet reached the primary endpoint of the trial, clinically-driven pre-
procedure fistulograms will be sent to the Independent Core Lab for analysis if they were performed by 
a radiologist who is not blind to the study treatment.  This will be sent regardless of whether the 
fistulogram is followed by a fistuloplasty. 
 
6. Assessment of Safety 
 
We have been informed by the MHRA that the PAVE protocol does not fall within the Clinical Trial 
Regulations and therefore is not a drug trial. In addition, the drug-coated balloon is a CE-marked 
medical device, so prior regulatory approval from the MHRA is not needed.   
 
Safety reporting will be in keeping with the requirements for research other than Clinical Trials of 
Investigational Medicinal Products.  
 
A Serious Adverse Event (SAE) is an untoward occurrence that:  
a) results in death 
b) is life-threatening  
c) requires non-elective hospitalisation or prolongation of existing hospitalisation  
d) results in persistent or significant disability or incapacity  
e) consists of a congenital anomaly or birth defect  
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f) is otherwise considered medically significant by the investigator.  
 
All SAEs will be reported by the local investigators on the SAE form to the Chief Investigator, 
immediately they become aware and within 24 hours at most. A planned or non-elective hospital 
admission does not need to be reported as an SAE unless the PI decides it should be. 
 
Although it is not an SAE, any pregnancy or fathering of children that occurs within 2 years of the 
study treatment will be reported via the SAE system as below. 
 
Reports of SAEs will be reviewed by the CI within 24 hours to assess whether the event is related to 
the research procedure and unexpected (a SUSAR) and if so, it will be onward reported to the REC 
and DMC within 15 days, in the format prescribed by NRES and published on the website. 
 
Since the study treatment is local and not systemic, non-serious adverse events will be defined as 
events that the PI considers are directly related to the vascular access that has been treated. These 
should be recorded throughout the trial and will be captured in the eCRF at each study assessment. 
 
7. Data Monitoring Committee    
 
The membership will be decided by the CI and approved by the NIHR. The DMC includes a statistician 
and two other independent experts.  They will receive a report of recruitment, serious and non-serious 
adverse events and a summary of accumulated clinical data from the trial statistician, and will meet in 
person or by telephone. They will report to the TSC who will usually meet in the two weeks following 
the DMC meeting. The DMC will meet at least annually during the study, approximately 2 weeks prior 
to the TSC. Additional meetings may take place at the time of interim analysis or in case of recruitment 
issues. The DMC is advisory to the TSC. The DMC charter will be drafted and agreed prior to 
recruitment. The Trial Statistician will prepare reports to the DMC. 
 
8. Trial Steering Committee    
 
The TSC will be convened in the post-award period. The membership will be decided by the CI and 
approved by the NIHR. The chair will be an independent expert.  Members will include the CI, a 
patient representative, and two other independent experts.  The TSC will meet at least annually during 
the study, approximately 2 weeks after the DMC. Additional meetings may take place at the time of 
interim analysis or in case of recruitment issues. The TSC is an executive committee. Terms of 
reference of the TSC will be agreed and documented prior to start of recruitment. The Trial Manager 
will prepare reports to the TSC. 
 
9. Ethics & Regulatory Approvals   
 
The trial will be conducted in compliance with the principles of the Declaration of Helsinki (1996), the 
principles of GCP and in accordance with all applicable regulatory requirements including but not 
limited to the Research Governance Framework.    
 
This protocol and related documents will be submitted for review to the London-Chelsea Research 
Ethics Committee (REC). 
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The Chief Investigator will submit a final report at conclusion of the trial to the sponsor and the REC.  
 
Annual progress reports will be submitted to the main REC for the study. 
 
10. Data Handling 
 
All samples will be anonymised before laboratory analysis. No patient-related data will be held in 
research laboratories.   
 
During the study, any paper documents will be held in a locked filing cabinet in a locked office and 
retained for a minimum of 5 years following the end of the study.   
 
Clinical and research data for the study will be stored on the eCRF system, hosted at the King’s 
Clinical Trials Unit, KCL. The eCRF (InferMed MACRO) is GCP and FDA 21 CFR Part 11 compliant. 
Data entry staff at site will be provided with unique usernames and passwords to the system and will 
be trained in data entry by the trial manager. The trial manager will visit sites to review data on the 
system, raise discrepancies and confirm source data verification checks.  All requests for access to 
the data entry system must be authorised by the trial manager. All requests for data exports must be 
authorised by the trial statistician. The trial manager will work with the CI and the trial statistician to 
ensure data is checked and cleaned on an ongoing basis and will confirm all data checks have been 
completed before database lock. 
 
The investigators and the institutions will permit trial-related monitoring, audits, REC review, and 
regulatory inspections (where appropriate) by providing direct access to source data and other 
relevant documents (i.e. patients’ case sheets, blood test reports, X-ray reports). Record keeping will 
be the responsibility of the investigators.   
 
11. Publication Policy 
 
It is intended that the results of the study will be reported and disseminated at international 
conferences and in peer-reviewed scientific journals. The chief investigator will review all 
presentations and publications arising from this study and decide authorship in accordance with 
accepted guidelines. 
 
12. Insurance / Indemnity 
 
The study will be indemnified by King’s College London for negligent and non-negligent harm.  In 
addition, the recruiting sites will have NHS indemnity. 
 
13. Financial Aspects 
 
The NIHR have supported the study through an EME programme grant award.  The fistuloplasty 
balloons are supplied by C.R. Bard, Inc. who have no other role in the design, running, or analysis of 
the trial.  
 
                                                                                                                                   
  Page 1 of 7 
VERSION CONTROL DOCUMENT – keep at front of Trial Master File 
 
THE MOST UP-TO-DATE VERSION OF EACH DOCUMENT MUST BE PLACED UPPERMOST IN THE FILE – Retain all earlier 
versions for audit purposes and mark: ‘Superseded by Version (No) on (date)’ to avoid accidental use of wrong version. 
 
Study Title (full): Paclitaxel assisted balloon Angioplasty of Venous stenosis in haEmodialysis access 
Study Title (short): PAVE 


































                                                                                                                                   









































                                                                                                                                   












































                                                                                                                                   







































7.0	 26/01/2017	 21/03/2017	 Study	Synopsis:	Exclusion	criterion	Point	4.	(page	4)	
                                                                                                                                   








































                                                                                                                                   










































                                                                                                                                   















King’s Clinical Trials Unit - KCTU  Confidential 
 
PAVE Statistical Analysis Plan 
 
PAVE Statistical Analysis Plan v1.0.doc v1.0                    Page 1 of 19   Current date: 30/04/2020     
 
 
Paclitaxel assisted balloon Angioplasty of Venous 
stenosis in haEmodialysis access (PAVE) 
 
A double-blind randomised controlled clinical trial to 
determine the efficacy of paclitaxel-assisted balloon 
angioplasty of venous stenosis in haemodialysis access 
 
Statistical Analysis Plan 
Version 1.0 
Version 1.0 started: 01/03/2016 
ISRCTN: 14284759 
This SAP has been written based on Protocol V4.0 
 
Trial Statistician: Emily Robinson 
 
Signature............................................        Date ................................... 
 
Chief Investigator: Dr Michael Robson 
 
Signature............................................        Date ................................... 
 
Trial Steering Committee Chair: Dr Richard Haynes 
 
Signature............................................        Date ................................... 
 
Data Monitoring Committee Statistician: Dr Isabel Reading 
 
Signature............................................        Date ................................... 
 
King’s Clinical Trials Unit - KCTU  Confidential 
 
PAVE Statistical Analysis Plan 
 
PAVE Statistical Analysis Plan v1.0.doc v1.0                    Page 2 of 19   Current date: 30/04/2020     
 
Contents	
1 QUANTITATIVE ANALYSIS PLAN ......................................................................................... 4 
1.1 Description of the trial ................................................................................................ 4 
1.1.1 Principal research objectives to be addressed .................................................... 4 
1.1.2 Trial design including blinding ............................................................................. 5 
1.1.3 Method of allocation of groups ........................................................................... 5 
1.1.4 Duration of the treatment period ....................................................................... 6 
1.1.5 Frequency and duration of follow-up .................................................................. 6 
1.1.6 Visit windows ....................................................................................................... 6 
1.1.7 Eligibility screening .............................................................................................. 6 
1.1.8 Measures ............................................................................................................. 6 
1.1.9 Sample size estimation (including clinical significance) ...................................... 8 
1.1.10 Brief description of proposed analyses ............................................................... 9 
1.2 Data analysis plan – Data description ....................................................................... 10 
1.2.1 Recruitment, eligibility and representativeness of patients ............................. 10 
1.2.2 Baseline comparability of randomised groups .................................................. 11 
1.2.3 Adherence to allocated treatment and treatment fidelity ............................... 11 
1.2.4 Loss to follow-up and other missing data ......................................................... 11 
1.2.5 Adverse event reporting .................................................................................... 11 
1.2.6 Assessment of outcome measures (unblinding) ............................................... 11 
1.2.7 Descriptive statistics for outcome measures .................................................... 11 
1.3 Data analysis plan – Inferential analysis ................................................................... 12 
1.3.1 Aims of formal inferences ................................................................................. 12 
1.3.2 Analysis of the primary outcome ...................................................................... 12 
1.3.3 Interim analysis .................................................................................................. 13 
1.3.4 Analysis of secondary outcomes ....................................................................... 15 
1.3.5 Stratification and clustering .............................................................................. 15 
1.3.6 Missing items in scales and subscales ............................................................... 15 
1.3.7 Missing baseline data ........................................................................................ 15 
1.3.8 Censoring and missing outcome data ............................................................... 15 
1.3.9 Method for handling multiple comparisons ...................................................... 16 
1.3.10 Method for handling non-compliance .............................................................. 16 
1.3.11 Model assumption checks ................................................................................. 16 
1.4 Sensitivity analyses ................................................................................................... 17 
1.4.1 Planned sensitivity analyses .............................................................................. 17 
King’s Clinical Trials Unit - KCTU  Confidential 
 
PAVE Statistical Analysis Plan 
 
PAVE Statistical Analysis Plan v1.0.doc v1.0                    Page 3 of 19   Current date: 30/04/2020     
 
1.4.2 Planned subgroup analyses ............................................................................... 17 
1.4.3 Competing risks analyses ................................................................................... 17 
1.4.4 Exploratory analyses .......................................................................................... 17 
1.5 Software .................................................................................................................... 17 
2 SCHEDULE OF ASSESSMENTS AND MEASURES ............................................................... 18 
3 REFERENCE LIST ............................................................................................................... 19 
King’s Clinical Trials Unit - KCTU  Confidential 
 
PAVE Statistical Analysis Plan 
 
PAVE Statistical Analysis Plan v1.0.doc v1.0                    Page 4 of 19   Current date: 30/04/2020     
 
1 QUANTITATIVE ANALYSIS PLAN	
 
This document details the presentation and analysis strategy for the primary paper 
reporting results from the PAVE trial. Subsequent papers of a more exploratory nature will 
not be bound by this analysis plan but will be expected to follow the broad principles laid 
down for the principle paper(s). The principles are not intended to curtail exploratory 
analysis or to prohibit sensible statistical and reporting practices. Rather, they are intended 
to establish the primary scientific objective of the study, including the primary comparison 
and primary outcome and the strategy that will be followed as closely as possible, when 
analysing and reporting the trial.  
 
Investigators 
Mr Keith Brennan 
Dr Kate Blake 
Dr Michael Robson 
Dr Narayan Karunanithy 
Mr Francis Calder 
 
Principal investigator 
Dr Michael Robson 
 
Trial manager 
Mrs Vikki Semik 
 
Trial statistician 
Dr Yanzhong Wang  
Miss Emily Robinson 
1.1 Description of the trial  
This is a double-blind, multicentre RCT to assess the efficacy of additional paclitaxel-coated 
balloon angioplasty compared to high-pressure balloon angioplasty only to preserve the 
patency of arteriovenous fistulae used for haemodialysis. 
1.1.1 Principal research objectives to be addressed  
The hypothesis is that we will demonstrate efficacy of paclitaxel-coated balloons in 
improving outcomes after fistuloplasty of stenotic arteriovenous fistulae. 
 
Primary objective  




To assess the difference between the two groups in:  
1. Angiographically determined late lumen loss 
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2. The rate of binary angiographic re-stenosis 
3. Time to end of access circuit primary patency  
4. Time to end of access circuit cumulative patency  
5. Procedural success 
6. Number of thrombosis events 
7. Number of fistula interventions 
8. Adverse events      
9. Patient quality of life assessed by EQ-5D and POS-S Renal 
 
A detailed description of trial objectives can be found in protocol section 2.1.  
1.1.2 Trial design including blinding  
The study is a double-blind multicentre randomised controlled trial, aiming to recruit 211 
patients over a two-year period. Randomisation will be at the level of the individual 
participants, minimising on radiologist performing the study procedure and whether the 
participant has had a previous radiological intervention in the access circuit or not. Follow 
up will be variable and for a minimum of one year; and all patients will continue in the study 
until the last patient has completed one year of follow up. 
1.1.3 Method of allocation of groups 
Recruitment and pre-screening procedures are described in the protocol sections 4.1-4.3.  
Once the patient has completed the pre-procedure fistulogram, high-pressure balloon 
fistuloplasty, and the completion fistulogram I, the radiologist will assess if the residual 
stenosis is ≤30%; if this is the case then the patient will proceed to randomisation.  
 
Randomisation will take place via a web based randomisation service, hosted at the UKCRC 
registered clinical trials unit at KCL. Site staff will access the service via www.ctu.co.uk using 
a computer in the angiography room or an office nearby. It will be performed by the 
radiologist performing the study procedure, or their nominee, and each randomiser will 
have unique user access. Access will be provided by the CTU upon the authorisation of the 
trial manager, once the delegation of authority form has been completed and relevant 
documentation regarding the individuals has been collected. Nominees must not be 
clinicians or nurses who may decide to refer the patient for re-intervention. 
 
As explained in 1.1.2, patients will be randomized using minimisation; this is performed with 
an 80% probability of allocating to the arm which reduces the imbalance. The allocation 
sequence will be generated dynamically so that the next allocation will only be generated 
and become known upon actioning a request from the study site staff. Once randomised, 
the system will automatically generate an email confirmation, which will be sent to relevant 
study staff in a blinded or unblinded format, depending on their role in the study: an unblind 
email is received by the trial manager and the radiologist who is performing the 
randomisation; and a blind email is received by the principal investigator and research 
nurses.  
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If it is not possible to use the randomisation system randomisation may occur using the toss 
of a coin in order to avoid losing the patient from the study. This should only be needed, if 
at all, in specific and rare situations such as the CTU server being inaccessible.  This will be 
performed by two people with heads denoting drug-coated balloon, and tails denoting 
placebo. The CTU must be informed of the coin randomisation as soon as possible. 
1.1.4 Duration of the treatment period  
Study treatment is described in detail in the protocol section 4.5. This is a one-off treatment 
that is administered within one study visit. Any repeat intervention is considered an event 
and therefore the end of the follow up.  
1.1.5 Frequency and duration of follow-up  
 
Study assessments will take place every 3 months. Follow up will be variable but for a 
minimum of 1 year and a maximum of 3 years. These will involve a clinical assessment to 
take place either face-to-face or via a telephone conversation. Any face-to-face meetings 
will usually coincide with dialysis to avoid additional patient travel. 
1.1.6 Visit windows  
 
At the time of each 3-month study assessment, an allowance of one month will be given 
either side to measure follow-up. This one month visit window will be the same for 
recording data throughout the follow-up period, i.e. 3-36 months post randomisation.  
1.1.7 Eligibility screening  
Patients that may be eligible will be identified in a vascular access clinic and assessed by 
surgeons, specialist nurses and nephrologists. In order to confirm there is a significant 
stenosis prior to angiography, a duplex ultrasound is encouraged but is not mandatory. At 
least 24 hours after being given the patient information sheet and before entering the 
angiography room for the pre-procedure fistulogram, consent will be taken and eligibility 
criteria will be assessed.   
Inclusion and exclusion criteria are described in sections 3.2 and 3.3 of the protocol. 
 
The radiologist who will perform the pre-procedure fistulogram, high-pressure balloon 
fistuloplasty and completion fistulogram will be informed that the patient is potentially 
eligible for the study, and they will assess the remaining eligibility criteria. 
1.1.8 Measures  
Baseline 
The following demographics will be measured at baseline: 
• Age (years) 
• Gender (male; female) 
• Ethnicity (White; Black; Asian; Mixed; Other) 
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The following clinical details will be measured at medical history screening: 
• Current diabetes diagnosis (yes; no) 
• Patient smoking history (current smoker; former smoker; never smoked) 
• Coronary artery disease (yes; no) 
• Peripheral vascular disease (yes; no) 
• Time since end-stage kidney failure (months) 
• Previous renal transplant(s) (number) 
• Total accumulated time with a functional renal transplant (months) 
• Total accumulated time patient has spent on haemodialysisis (months) 
• Total accumulated time patient has spent on peritoneal dialysis (months) 
• Location of fistula (right arm; left arm) 
• Type of native fistula (Radio-cephalic; Brachio-cephalic; Basilic vein transposition; 
Ulnar-cephalic) 
• Time since fistula was formed (months) 
• Time since fistula was first used (months) 
• Current access circuit previously had a thrombosis (yes; no) 
• Previous surgical interventions to the current access circuit (number) 
• Previous fistuloplasties to the current access circuit (number) 
• Primary indication for the index procedure (inadequate dialysis; poor fistula blood 
flow; prolonged bleeding; high venous pressures; low arterial pressure; difficulty 
needling; other evidence of fistula dysfunction) 
 
The following clinical details will be measured at the pre-procedure fistulogram: 
• Location of stenosis (juxta-anastamotic; venous segment; cephalic arch; after 
cephalic arch and not beyond the thoracic inlet; beyond the thoracic inlet) 
• Degree of stenosis (5%) 
• Length of stenosis (mm) 
• Radiologist (initials) 
 
The following clinical details will be measured at the treatment fistuloplasty: 
• Index lesion vessel diameter (mm) 
• Diameter of plain balloon used (mm) 
• Length of plain balloon used (mm) 
• Pressure to which used plain balloon was inflated (atm) 
• Number of unsuccessful attempts at plain balloon fistuloplasty (0-2) 
• Complications due to plain balloon fistuloplasty (vessel rupture; balloon rupture; 
vein thrombosis; venous vasospasm; other; none) 
• Diameter of study treatment balloon used (mm) 
• Length of study treatment balloon used (mm) 
• Pressure to which study treatment balloon was inflated (atm) 
• Complications of the study treatment fistuloplasty (vessel rupture; balloon rupture; 
vein thrombosis; venous vasospasm; other; none) 
• Residual stenosis still 30% or less after study treatment (yes; no) 
• Further fistuloplasty performed after study treatment (yes; no) 
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• Type of balloon from further fistuloplasty (Dorado; other) 
• Diameter of balloon from further fistuloplasty (mm) 
• Length of balloon from further fistuloplasty (mm) 
• Residual stenosis 30% or less after further fistuloplasty (yes; no) 
• Complications due to further fistuloplasty (vessel rupture; balloon rupture; vein 
thrombosis; venous vasospasm; other; none) 
• Radiologist (initials) 
 
Primary outcome measures  
The primary outcome measure is time to Target Lesion Primary Patency (TLPP). This will be 
measured in days post treatment fistuloplasty. 
 
Secondary outcome measures 
The secondary outcomes, as listed in 1.1.1, will be measured as follows: 
1. Late lumen loss (mm); the difference between the diameter of the lesion at the 
completion fistulogram II (baseline) and at the protocol fistulogram (6 months) 
2. Rate of binary angiographic re-stenosis (%); at the protocol fistulogram (6 months) 
3. Time to loss of access circuit primary patency (days post treatment fistuloplasty) 
4. Time to loss of access circuit cumulative patency (days post treatment fistuloplasty) 
5. Procedural success (yes; no); stenosis ≤30% at completion fistulogram II (baseline) 
6. Thrombosis events (number); recorded as fistula interventions throughout the trial 
7. Fistula interventions (number); recorded throughout the trial 
8. Adverse events (number); recorded throughout the trial 
9. Patient quality of life; EQ-5D and POS-S Renal scores 
 
Adverse events 
The following adverse event measures will be collected at 6 and 12 months post 
randomisation, and at withdrawal, where applicable: 
• Adverse Event (Oedema of hand or arm; Pseudoaneurysm; Haematoma; Distal 
Ischaemia; Neurological complications; Infection localised to fistula; Central venous 
catheter insertions; other) 
• Duration of event (days) 
• Intensity (mild; moderate; severe) 
• Outcome (resolved; resolved with sequelae; ongoing; death; unknown) 
• Related to study intervention (definite; probable; possible; remote; none) 
• Serious Adverse Event (yes; no) 
• Ongoing at end of study (yes; no) 
 
Please refer to section 2 for the schedule of assessments and measures. 
1.1.9 Sample size estimation (including clinical significance)  
For the definition of the survival curve in the placebo balloon group, we assumed target 
lesion primary patency of 61%, 42%, and 35% at 6, 12 and 24 months respectively.  This was 
consistent with published results {Bountouris:2014dy, Tessitore:2003ty} and with our own 
audit data. A hazard ratio (HR) of 0.5 was chosen as the minimum clinically relevant effect 
King’s Clinical Trials Unit - KCTU  Confidential 
 
PAVE Statistical Analysis Plan 
 
PAVE Statistical Analysis Plan v1.0.doc v1.0                    Page 9 of 19   Current date: 30/04/2020     
 
size {Katsanos:2012hd} found a HR of 0.3 for Target Lesion Primary Patency at 6 months; 
however, the confidence interval was broad and the effect size is expected to be closer to 
the null when AVGs are excluded. Based on these assumptions, it is expected that the 
paclitaxel coated balloon group will show 78%, 65%, and 59% survival of TLPP at 6, 12 and 
24 months respectively.  Recruiting 211 patients, with variable follow up, a minimum follow 
up of 1 year, and three interim analyses, will provide 94% power to detect a statistically 
significant difference between the two groups in TLPP survival with 2-sided 5% type I error 
rate. It is expected that 108 patients will experience fistula failure during the follow up 
period, 66 in the control arm, and 42 in the intervention arm.  
 
The required sample size has been estimated assuming cumulative 10% drop-out in each 
treatment arm by the end of the study, which would result in 6 patients in the treatment 
arm, and 3 in the control arm. We have planned for a recruitment rate of 2 patients per 
month (ppm) during the first three months, 8 ppm up to 7 months, and 12 ppm onwards. 
The expected accrual duration will be 22 months, and the maximum study duration 
(including follow-up) 34 months.   
1.1.10 Brief description of proposed analyses  
Analyses will be carried out by the trial statistician (ER) once the database has been locked. 
Data will be analysed with an intention-to-treat approach (i.e. analyse all those with data in 
groups as randomised irrespective of treatment received).  
 
There will be descriptives statistics reported on the measures mentioned in 1.1.8, with an 
aim to comparing the treatment arms, and to review the patient demographics. 
 
For the primary analysis, to test the superiority of the paclitaxel-coated balloon treatment 
group compared to placebo balloon in TLPP survival, Cox-Proportional Hazards regression 
will be used. This will be repeated using multivariate cox regression for the adjustment of 
the treatment effect size for the effect of known clinical covariates; which are listed in detail 
in section 1.3.2. 
 
Effects on secondary outcomes will be analysed using the same strategy for time-to-event 
variables, and generalized linear models for binary and continuous outcome measures, 
adjusting for the effects of relevant covariates when appropriate.  
 
Interim analysis of the primary outcome will be performed three times throughout the 
study, based on the cumulative number of failures of the treatment area. 
 
Further details of the analyses are given later on in this document.  
 
Data summaries and analyses will be carried out in Stata 14.0. 
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1.2 Data analysis plan – Data description 
1.2.1 Recruitment, eligibility and representativeness of patients 
A CONSORT flow chart will be constructed – see Figure 1. The number of patients will be 
summarised using the following categories: total number of patients screened; eligible; 
consenting; and randomised. 
 
Then by treatment arm: patients compliant and non-compliant with intervention; 
continuing through the trial; withdrawing; lost to follow-up; and excluded or analysed. 
 
Compliance (adherence) is defined as receiving the following procedures: plain balloon 
fistuloplasty; completion fistulogram I; study treatment fistuloplasty; and completion 
fistulogram II. 
 
A summary of the number of patients compliant with the study treatment will be provided 
and stratified by study centre. 
 
 
Figure 1.  Template CONSORT diagram for PAVE trial  
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1.2.2 Baseline comparability of randomised groups  
All baseline variables listed under measures in section 1.1.8 will be reported by trial arm and 
overall. They will be grouped into patient demographics and patient clinical information, 
and reported as: minimums and maximums, means and standard deviation, medians and 
quartiles for continuous variables as appropriate; and frequencies and proportions for 
categorical variables. No significance testing will be used to test baseline differences 
between the trial arms. 
1.2.3 Adherence to allocated treatment and treatment fidelity  
Adherence to allocated treatment (compliant versus non-compliant), as described in 1.2.1, 
and the reasons for not completing the treatment process will be summarised using the 
treatment fistuloplasty form. Adherence will be compared between trial arm using baseline 
variables; and the reasons for withdrawal from treatment will be summarised.  
1.2.4 Loss to follow-up and other missing data 
Withdrawal from trial follow-up (attrition rate) will be reported by intervention group, 
including reasons for withdrawal. The proportions of participants missing each variable will 
be summarised in each arm and at each study visit.  
 
If necessary, multiple imputation will be used for the imputation of missing values in 
baseline variables and secondary outcomes. Patients with TLPP at the end of follow up will 
be considered censored, as will those who receive a renal transplant, switch to peritoneal 
dialysis or are lost to follow up before the study end.   
 
The baseline characteristics and adverse events of patients lost to follow up will be 
compared to those with complete follow up data. The relationship between these and 
missing data will be investigated graphically to see if baseline characteristics or adverse 
events predict missing, i.e. drop-outs are not random. 
1.2.5 Adverse event reporting  
Adverse events (AE), adverse reactions (AR), serious adverse events (SAE) and serious 
adverse reactions (SAR) will be summarised by trial arm and overall. 
1.2.6 Assessment of outcome measures (unblinding) 
Outcome assessors and the trial statistician are being kept blind to treatment allocation.  
1.2.7 Descriptive statistics for outcome measures  
The primary and secondary outcomes as listed in section 1.1.8 will be described by 
treatment group and time point. Means and standard deviations or medians and 
interquartile ranges will be used for continuous variables, where relevant; this will check 
whether continuous outcomes can be assumed normally distributed. Kaplan-Meier plots, 
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hazard-ratio and its confidence interval will be used to describe the time to event results. 
Frequencies and proportions will be used to describe binary variables. 
1.3 Data analysis plan – Inferential analysis  
1.3.1 Aims of formal inferences 
The formal statistical analyses will estimate the differences in relevant variables (time to 
event, quality of life) between patients randomised to the paclitaxel-coated balloon 
angioplasty compared to high-pressure placebo balloon angioplasty, by intention to treat. 
 
As mentioned in section 1.2.4, for the primary outcome and other time to event variables, 
patients lost to follow-up will be right censored; this means they are counted as not having 
experienced end of target lesion primary patency, or the relevant event, for the period of 
time we have data on them. If dropout is related to both outcome and treatment, then 
dropouts may bias the results. 
 
Group difference estimates and associated 95% confidence intervals will be reported. The 
trial statistician will remain blind until the main analyses have been completed. The overall 
significance level will be 5% (two-sided) for the primary and secondary outcomes. 
Significance level of final analysis of primary outcome will be determined by the alpha 
spending function used to plan interim analyses.  
 
Details on the methods for handling missing data are given in sections 1.3.8.  
 
Sensitivity analyses will be used to assess the robustness of conclusions; please refer to 
section 1.4 for details of the planned sensitivity and subgroup analyses. 
1.3.2 Analysis of the primary outcome 
The analysis population will include all patients randomised with sufficient information to 
carry out the analysis, i.e. complete primary outcome data and minimisation factors. The 
primary outcome is time to end of target lesion primary patency (TLPP); measured as days 
post randomisation. For the purpose of the primary outcome analysis, this will be taken as 
recorded by the target lesion primary patency form.  
 
Expected time to end of TLPP will be calculated using the hazard ratio estimated by the 
model explained below. Survival analysis methods will be used to compare the primary 
outcome for the two groups as this can factor in censoring and time.  
 
Kaplan-Meier plots will be used to graphically illustrate and compare the observed 
probabilities of target lesion primary patency past certain times in the trial period, taking 
into account censoring, for the two trial arms. This is a non-parametric estimate of the 
survival function over the analysis time, and will also be used to check the Cox 
proportionality assumption – see section 1.3.10.  
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Cox-Proportional Hazards regression will be used to model the effect of predictors and 
covariates on the hazard rate and estimate the relative risk by trial arm. This will be 
compared to an initial estimate from the null model where the model will be fitted without 
any covariates. Model components included in the primary model will be a baseline hazard 
function that is unspecified but positive; previous radiological intervention in the access 
circuit; trial centre; trial arm; observed study time (length of time between patient entering 
and exiting study); and a trial arm*observed time interaction term. The interaction term 
allows for variable follow-up time effects. 
 
A secondary adjusted analysis will be fit to evaluate the impact of baseline covariates on the 
size of the treatment effect. The covariates considered will be: baseline characteristics 
(ethnicity; age; diabetes diagnosis; and smoking history) and clinical variables at baseline 
(total time on haemodialysis; time since end stage kidney failure; type of native fistula; 
previous circuit intervention; and location of stenosis). 
 
The relationship between baseline variables and missing outcome data will be assessed 
using logistic regression with an outcome variable that represents whether outcome data 
are present or missing. Should any baseline variables be predictive of missing then these will 
be included in the primary analysis Cox regression models as further covariates.  
1.3.3 Interim analysis 
Interim analysis of the primary outcome will be performed three times throughout the 
study, based on the cumulative number of failures in the primary outcome, i.e. after 27, 54 
and 81 events, expected approximately at 9, 14 and 19 months of study under the null, and 
at months 11, 17, and 23 under the alternative hypothesis. Group sequential stopping 
boundaries have been calculated using a Lan-de-Mets spending function (with O’Brian-
Fleming parameters), to allow early stopping for rejection of the null or the alternative 
hypotheses. Stopping in case of boundary crossing is non-binding and will be discussed with 
the DMEC members during a closed session that does not include any trial members who 
are blinded. 
 
The Hazard Ratio used to evaluate the crossing of stopping boundaries will be calculated 
with a Cox-proportional hazards regression that includes centre, and presence or absence of 
previous interventions as covariates, as well as treatment group as independent variable of 
interest.  
 
Stopping boundaries are displayed in the figure below: 
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The table below shows further details of the stopping boundaries, including expected 





Stopping boundaries in the table are expressed in the HR scale.  
Test statistics for interim analysis will be calculated with standard statistics software 
packages (R or Stata), and entered into the interim monitoring tool of the East software in 
order to check crossing of boundaries, and calculate effect size and conditional power.  
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Interim analyses will be programmed by the trial statistician, but run and summarised by an 
independent statistician.  
1.3.4 Analysis of secondary outcomes 
Secondary patient outcomes relating to time-to-event variables, for example, time to end of 
access circuit primary patency, will be analysed using Cox regression models in a similar 
method to above.  
 
Continuous variables such as POS-S Renal score for quality of life, will be checked for 
normality, transformed if necessary and analysed using linear regression models. Otherwise, 
they will be analysed using a Wilcoxon-signed-rank test for independent samples. Logistic 
regression models will be used for binary secondary outcomes, for example, procedural 
success (rate of binary angiographic re-stenosis ≥50%) at the six month protocol fistulogram. 
 
Similarly to the primary outcome analysis, covariates considered in the models will include: 
baseline measure of outcome variable, where applicable; minimisation factors; trial arm; 
and time in study. An interaction term will also be included between observed study time 
and study treatment, as above. 
1.3.5 Stratification and clustering 
Randomisation is on the patient level, minimising on radiologist performing the study 
treatment and previous radiological intervention to treatment area or not; therefore these 
variables will be included as covariates in the modelling process, as mentioned in section 
1.3.2. However, the data should not have a clustered structure so this does not need to be 
accounted for. 
1.3.6 Missing items in scales and subscales 
The number (%) with complete data will be reported.  The ideal approach would be to use 
missing value guidance provided for scales.  
1.3.7 Missing baseline data 
We do not anticipate missing values in pre-randomisation variables. However, if we 
encounter missing baseline values then these can be singly imputed according to White and 
Thompson[3] without incurring bias of the treatment effect estimate. 
1.3.8 Censoring and missing outcome data  
For time to event outcomes, patient data is considered censored when the patient is 
withdrawn from follow-up, i.e. it is only known that the amount of time to event for that 
patient is greater than some value. Censoring will also happen at the end of the study, if the 
patient does not experience the primary endpoint before end of follow-up. In the analysis, 
the censored observations will be included in the number of patients at risk in respect to 
their observed study time (survival time).  
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For non-time to event outcomes, missing post-randomisation assessments will be dealt with 
by fitting generalised mixed models to all the available data using maximum likelihood 
methods. Such an approach provides valid inferences under the assumption that the missing 
data mechanism is ignorable (or MAR). This allows for missingness at later times to be 
predicted by outcome values at earlier times. If post treatment variables such as compliance 
with study procedures are found to be predictive of drop out, multiple imputation will be 
considered. 
1.3.9 Method for handling multiple comparisons  
Analysis of secondary outcomes is considered exploratory, and therefore there will be no 
correction for multiple testing. However, care should be given to the interpretation of 
inference for the numerous secondary outcomes and it may be necessary to assess the 
agreement between similar outcome measures. Cohen's Kappa statistic and/or Spearman’s 
rank correlation coefficients may be used to test for inter-participant reliability and to 
measure the degree of linear association between two outcomes. For example, 
angiographically determined late lumen loss and the rate of binary angiographic re-stenosis 
would be expected to be highly predictive of one another.  
1.3.10 Method for handling non-compliance  
In addition to the primary intention-to-treat analysis the effect of actually receiving 
treatment as defined in the protocol will also be estimated. 
 
There is not expected to be a problem with non-compliance due to the design of the trial. 
1.3.11 Model assumption checks  
In order to assess the adequacy of the Cox regression models for the primary outcome and 
time-to-event secondary outcomes, the main assumption to test for is proportionality; the 
Kaplan-Meier plots will be used to check if the curves for the two trial arms are the same 
shape, and if the separation of the curves remains proportionate throughout the analysis 
period.  
 
In addition, time-dependent covariates will be generated by creating interactions of the 
predictors and function of survival time; if these are significant then the predictors are not 
proportional.  
 
If the assumption for proportionality is violated then the consequence this has on the 
results can be checked. The Cox model can be stratified according to the variables with non-
proportional hazards to see whether that changes the hazard ratios for the variables of 
interest; if it still does, then it may be necessary to use an alternative model. One 
parametric alternative is the Royston-Parmar model, which is more flexible and can fit a 
non-proportional hazards model. 
 
For the other secondary outcomes regression residuals will be plotted to check for normality 
and outliers, where applicable. 
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1.4 Sensitivity analyses  
1.4.1 Planned sensitivity analyses 
A sensitivity analysis will be performed using adjudicated data from the core lab readings, in 
comparison to the primary analysis where the events reported in the trial will be used. This 
will assess the robustness of the trial findings by clarifying whether the primary analysis 
conclusions are impacted by any methodological issues, such as outcome definitions. 
1.4.2 Planned subgroup analyses  
Subgroup analyses will be carried out to assess whether the observed effect is consistent 
across patient categories; to do this, an interaction term will be included in the Cox 
proportional hazards model between the exposure (study treatment group) and the 
subgroup variable. 
  
The planned subgroups will be: second minimisation factor (previous radiological 
intervention to the treatment area or not); smoking history (current smoker, former 
smoker, never smoked); baseline diabetes diagnosis (yes, no); current total time on 
haemodialysis (quartiles); total time since end stage kidney failure (quartiles); type of native 
fistula (Radio-cephalic, Brachio-cephalic, Basilic vein transposition, Ulnar-cephalic); and 
location of stenosis (juxta-anastomotic, venous segment, cephalic arch, between cephalic 
arch and thoracic inlet).  
1.4.3 Competing risks analyses 
To assess the influence of events that may prevent other events from being observed, 
competing risks analyses will be planned to adjust for these. Specifically, ‘irrelevant’ deaths 
and re-transplantations will be defined as competing risks rather than censored events. The 
cause of death will be checked from hospital notes and/or death certificates. 
1.4.4 Exploratory analyses  
 
This analysis plan does not cover secondary exploratory analysis. Exploratory mediator and 
moderator analyses may be performed after the primary trial data analysis. 
1.5 Software 
Data management: An online data collection system for clinical trials (MACRO; InferMed 
Ltd) will be used. This is hosted on a dedicated server at KCL and managed by the KCTU.  The 
KCTU Data Manager will extract data periodically as needed and requests will usually be 
made by the trial statistician. There will be several database extracts throughout the trial for 
each DMEC Report, and a final extract after data lock. Data will be provided in comma 
separated (.csv) format.  
 
Statistical analysis: Stata and or R will be used for data description and inferential analysis.   
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01. Registration form 5 X                
02. Eligibility form  14 X                
03. Medical History form  19 X                
04. Haematology and 
Biochemistry form 
11 X  X X X            
05. Pre-procedure Fistulogram 
form 
8  X                   
06. Randomisation form 4  X               
07. Treatment Fistuloplasty 
form 
46  X               
08. Fistula Intervention form 
(repeating) 
32                X 
09. Month 6 Fistula Function 
form 
9     X            
10. Protocol Fistulogram form  11     X            
11. POS-S Renal questionnaire 25 X    X  X          
12. EQ-5D questionnaire 6 X    X  X          
13. Medications form 17 X   X X X X X X X X X X X X  
14. Adverse Events form 9                X 
15. Withdrawal form 5                X 
16. Status form 5    X X X X X X X X X X X X  
17. Loss of Patency form 
(repeating) 
9                X 
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1 QUANTITATIVE ANALYSIS PLAN	
 
This document details the presentation and analysis strategy for the primary paper 
reporting results from the PAVE trial. Subsequent papers of a more exploratory nature will 
not be bound by this analysis plan but will be expected to follow the broad principles laid 
down for the principle paper(s). The principles are not intended to curtail exploratory 
analysis or to prohibit sensible statistical and reporting practices. Rather, they are intended 
to establish the primary scientific objective of the study, including the primary comparison 
and primary outcome and the strategy that will be followed as closely as possible, when 
analysing and reporting the trial.  
 
Investigators 
Mr Keith Brennan 
Dr Kate Blake 
Dr Michael Robson 
Dr Narayan Karunanithy 
Mr Francis Calder 
 
Principal investigator 
Dr Michael Robson 
 
Trial managers 
Dr Leanne Gardner 
Ms Michaela Curran 
 
Trial statisticians 
Dr Yanzhong Wang  
Miss Emily Robinson 
1.1 Description of the trial  
This is a double-blind, multicentre RCT to assess the efficacy of additional paclitaxel-coated 
balloon angioplasty compared to high-pressure balloon angioplasty only to preserve the 
patency of arteriovenous fistulae used for haemodialysis. 
1.1.1 Principal research objectives to be addressed  
The hypothesis is that we will demonstrate efficacy of paclitaxel-coated balloons in 
improving outcomes after fistuloplasty of stenotic arteriovenous fistulae. 
 
Primary objective  




To assess the difference between the two groups in:  
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1. Angiographically determined late lumen loss 
2. The rate of binary angiographic re-stenosis 
3. Time to end of access circuit primary patency  
4. Time to end of access circuit cumulative patency  
5. Procedural success 
6. Number of thrombosis events 
7. Number of fistula interventions 
8. Adverse events      
9. Patient quality of life assessed by EQ-5D and POS-S Renal 
 
A detailed description of trial objectives can be found in protocol section 2.1.  
1.1.2 Trial design including blinding  
The study is a double-blind multicentre randomised controlled trial, aiming to recruit 211 
patients over a two-year period. Randomisation will be at the level of the individual 
participants, minimising on radiologist performing the study procedure; whether the patient 
has had a previous radiological intervention in the access circuit or not; and whether the 
patient is currently on haemodialysis. Follow up will be variable and for a minimum of one 
year; and all patients will continue in the study until the last patient has completed one year 
of follow up. 
1.1.3 Method of allocation of groups 
Recruitment and pre-screening procedures are described in the protocol sections 4.1-4.3.  
Once the patient has completed the pre-procedure fistulogram, high-pressure balloon 
fistuloplasty, and the completion fistulogram I, the radiologist will assess if the residual 
stenosis is ≤30%; if this is the case then the patient will proceed to randomisation.  
 
Randomisation will take place via a web based randomisation service, hosted at the UKCRC 
registered clinical trials unit at KCL. Site staff will access the service via www.ctu.co.uk using 
a computer in the angiography room or an office nearby. It will be performed by the 
radiologist performing the study procedure, or their nominee, and each randomiser will 
have unique user access. Access will be provided by the CTU upon the authorisation of the 
trial manager, once the delegation of authority form has been completed and relevant 
documentation regarding the individuals has been collected. Nominees must not be 
clinicians or nurses who may decide to refer the patient for re-intervention. 
 
As explained in 1.1.2, patients will be randomized using minimisation; this is performed with 
an 80% probability of allocating to the arm which reduces the imbalance. The allocation 
sequence will be generated dynamically so that the next allocation will only be generated 
and become known upon actioning a request from the study site staff. Once randomised, 
the system will automatically generate an email confirmation, which will be sent to relevant 
study staff in a blinded or unblinded format, depending on their role in the study: an unblind 
email is received by the trial manager and the radiologist who is performing the 
randomisation; and a blind email is received by the principal investigator and research 
nurses.  
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If it is not possible to use the randomisation system randomisation may occur using the toss 
of a coin in order to avoid losing the patient from the study. This should only be needed, if 
at all, in specific and rare situations such as the CTU server being inaccessible.  This will be 
performed by two people with heads denoting drug-coated balloon, and tails denoting 
placebo. The CTU must be informed of the coin randomisation as soon as possible. 
1.1.4 Duration of the treatment period  
Study treatment is described in detail in the protocol section 4.5. This is a one-off treatment 
that is administered within one study visit. Any repeat intervention is considered an event 
and therefore the end of the follow up.  
1.1.5 Frequency and duration of follow-up  
 
Study assessments will take place every 3 months. Follow up will be variable but for a 
minimum of 1 year. These will involve a clinical assessment to take place either face-to-face 
or via a telephone conversation. Any face-to-face meetings will usually coincide with dialysis 
to avoid additional patient travel. 
1.1.6 Visit windows  
 
At the time of each 3-month study assessment, an allowance of one month will be given 
either side to measure follow-up. This one month visit window will be the same for 
recording data throughout the follow-up period.  
1.1.7 Eligibility screening  
Patients that may be eligible will be identified in a vascular access clinic and assessed by 
surgeons, specialist nurses and nephrologists. In order to confirm there is a significant 
stenosis prior to angiography, a duplex ultrasound is encouraged but is not mandatory. At 
least 24 hours after being given the patient information sheet and before entering the 
angiography room for the pre-procedure fistulogram, consent will be taken and eligibility 
criteria will be assessed.   
Inclusion and exclusion criteria are described in sections 3.2 and 3.3 of the protocol. 
 
The radiologist who will perform the pre-procedure fistulogram, high-pressure balloon 
fistuloplasty and completion fistulogram will be informed that the patient is potentially 
eligible for the study, and they will assess the remaining eligibility criteria. 
1.1.8 Measures  
Baseline 
The following demographics will be measured at baseline: 
• Age (years) 
• Gender (male; female) 
• Ethnicity (White; Black; Asian; Mixed; Other) 
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The following clinical details will be measured at medical history screening: 
• Current diabetes diagnosis (yes; no) 
• Patient smoking history (current smoker; former smoker; never smoked) 
• Coronary artery disease (yes; no) 
• Peripheral vascular disease (yes; no) 
• Time since end-stage kidney failure (months) 
• Previous renal transplant(s) (number) 
• Total accumulated time with a functional renal transplant (months) 
• Total accumulated time patient has spent on haemodialysisis (months) 
• Total accumulated time patient has spent on peritoneal dialysis (months) 
• Location of fistula (right arm; left arm) 
• Type of native fistula (Radio-cephalic; Brachio-cephalic; Basilic vein transposition; 
Ulnar-cephalic) 
• Time since fistula was formed (months) 
• Time since fistula was first used (months) 
• Current access circuit previously had a thrombosis (yes; no) 
• Previous surgical interventions to the current access circuit (number) 
• Previous fistuloplasties to the current access circuit (number) 
• Primary indication for the index procedure (inadequate dialysis; poor fistula blood 
flow; prolonged bleeding; high venous pressures; low arterial pressure; difficulty 
needling; other evidence of fistula dysfunction) 
 
The following clinical details will be measured at the pre-procedure fistulogram: 
• Location of stenosis (juxta-anastamotic; venous segment; cephalic arch; after 
cephalic arch and not beyond the thoracic inlet; beyond the thoracic inlet) 
• Degree of stenosis (5%) 
• Length of stenosis (mm) 
• Radiologist (initials) 
 
The following clinical details will be measured at the treatment fistuloplasty: 
• Index lesion vessel diameter (mm) 
• Diameter of plain balloon used (mm) 
• Length of plain balloon used (mm) 
• Pressure to which used plain balloon was inflated (atm) 
• Number of unsuccessful attempts at plain balloon fistuloplasty (0-2) 
• Complications due to plain balloon fistuloplasty (vessel rupture; balloon rupture; 
vein thrombosis; venous vasospasm; other; none) 
• Diameter of study treatment balloon used (mm) 
• Length of study treatment balloon used (mm) 
• Pressure to which study treatment balloon was inflated (atm) 
• Complications of the study treatment fistuloplasty (vessel rupture; balloon rupture; 
vein thrombosis; venous vasospasm; other; none) 
• Residual stenosis still 30% or less after study treatment (yes; no) 
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• Further fistuloplasty performed after study treatment (yes; no) 
• Type of balloon from further fistuloplasty (Dorado; other) 
• Diameter of balloon from further fistuloplasty (mm) 
• Length of balloon from further fistuloplasty (mm) 
• Residual stenosis 30% or less after further fistuloplasty (yes; no) 
• Complications due to further fistuloplasty (vessel rupture; balloon rupture; vein 
thrombosis; venous vasospasm; other; none) 
• Radiologist (initials) 
 
Primary outcome measures  
The primary outcome measure is time to Target Lesion Primary Patency (TLPP). This will be 
measured in days post treatment fistuloplasty. 
 
Secondary outcome measures 
The secondary outcomes, as listed in 1.1.1, will be measured as follows: 
1. Late lumen loss (mm); the difference between the diameter of the lesion at the 
completion fistulogram II (baseline) and at the protocol fistulogram (6 months) 
2. Rate of binary angiographic re-stenosis (%); at the protocol fistulogram (6 months) 
3. Time to loss of access circuit primary patency (days post treatment fistuloplasty) 
4. Time to loss of access circuit cumulative patency (days post treatment fistuloplasty) 
5. Procedural success (yes; no); stenosis ≤30% at completion fistulogram II (baseline) 
6. Thrombosis events (number); recorded as fistula interventions throughout the trial 
7. Fistula interventions (number); recorded throughout the trial 
8. Adverse events (number); recorded throughout the trial 
9. Patient quality of life; EQ-5D and POS-S Renal scores 
 
Adverse events 
The following adverse event measures will be collected at 6 and 12 months post 
randomisation, and at withdrawal, where applicable: 
• Adverse Event (Oedema of hand or arm; Pseudoaneurysm; Haematoma; Distal 
Ischaemia; Neurological complications; Infection localised to fistula; Central venous 
catheter insertions; other) 
• Duration of event (days) 
• Intensity (mild; moderate; severe) 
• Outcome (resolved; resolved with sequelae; ongoing; death; unknown) 
• Related to study intervention (definite; probable; possible; remote; none) 
• Serious Adverse Event (yes; no) 
• Ongoing at end of study (yes; no) 
 
Please refer to section 2 for the schedule of assessments and measures. 
1.1.9 Sample size estimation (including clinical significance)  
For the definition of the survival curve in the placebo balloon group, we assumed target 
lesion primary patency of 61%, 42%, and 35% at 6, 12 and 24 months respectively.  This was 
consistent with published results (Bountouris, 2014; Tessitore, 2003) and with our own audit 
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data. A hazard ratio (HR) of 0.5 was chosen as the minimum clinically relevant effect size; 
(Katsanos, 2012) found a HR of 0.3 for Target Lesion Primary Patency at 6 months, however, 
the confidence interval was broad and the effect size is expected to be closer to the null 
when AVGs are excluded. Based on these assumptions, it is expected that the paclitaxel 
coated balloon group will show 78%, 65%, and 59% survival of TLPP at 6, 12 and 24 months 
respectively.  Recruiting 211 patients, with variable follow up, a minimum follow up of 1 
year, and three interim analyses, will provide 94% power to detect a statistically significant 
difference between the two groups in TLPP survival with 2-sided 5% type I error rate. It is 
expected that 108 patients will experience fistula failure during the follow up period, 66 in 
the control arm, and 42 in the intervention arm.  
 
The required sample size has been estimated assuming cumulative 10% drop-out in each 
treatment arm by the end of the study, which would result in 6 patients in the treatment 
arm, and 3 in the control arm. We have planned for a recruitment rate of 2 patients per 
month (ppm) during the first three months, 8 ppm up to 7 months, and 12 ppm onwards. 
The expected accrual duration will be 22 months, and the maximum study duration 
(including follow-up) 34 months.   
1.1.10 Brief description of proposed analyses  
Analyses will be carried out by the trial statistician (ER) once the database has been locked. 
Data will be analysed with an intention-to-treat approach (i.e. analyse all those with data in 
groups as randomised irrespective of treatment received).  
 
There will be descriptives statistics reported on the measures mentioned in 1.1.8, with an 
aim to comparing the treatment arms, and to review the patient demographics. 
 
For the primary analysis, to test the superiority of the paclitaxel-coated balloon treatment 
group compared to placebo balloon in TLPP survival, Cox-Proportional Hazards regression 
will be used. This will be repeated using multivariate cox regression for the adjustment of 
the treatment effect size for the effect of known clinical covariates; which are listed in detail 
in section 1.3.2. 
 
Effects on secondary outcomes will be analysed using the same strategy for time-to-event 
variables, and generalized linear models for binary and continuous outcome measures, 
adjusting for the effects of relevant covariates when appropriate.  
 
Interim analysis of the primary outcome will be performed up to three times throughout the 
study, based on the cumulative number of failures of the treatment area. 
 
Further details of the analyses are given later on in this document.  
 
Data summaries and analyses will be carried out in Stata 14.0. 
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1.2 Data analysis plan – Data description 
1.2.1 Recruitment, eligibility and representativeness of patients 
A CONSORT flow chart will be constructed – see Figure 1. The number of patients will be 
summarised using the following categories: total number of patients screened; eligible; 
consenting; and randomised. 
 
Then by treatment arm: patients compliant and non-compliant with intervention; 
continuing through the trial; withdrawing; lost to follow-up; and excluded or analysed. 
 
Compliance (adherence) is defined as receiving the following procedures: plain balloon 
fistuloplasty; completion fistulogram I; study treatment fistuloplasty; and completion 
fistulogram II. 
 
A summary of the number of patients compliant with the study treatment will be provided 
and stratified by radiologist. 
 
 
Figure 1.  Template CONSORT diagram for PAVE trial  
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1.2.2 Baseline comparability of randomised groups  
All baseline variables listed under measures in section 1.1.8 will be reported by trial arm and 
overall. They will be grouped into patient demographics and patient clinical information, 
and reported as: minimums and maximums, means and standard deviation, medians and 
quartiles for continuous variables as appropriate; and frequencies and proportions for 
categorical variables. No significance testing will be used to test baseline differences 
between the trial arms. 
1.2.3 Adherence to allocated treatment and treatment fidelity  
Adherence to allocated treatment (compliant versus non-compliant), as described in 1.2.1, 
and the reasons for not completing the treatment process will be summarised using the 
treatment fistuloplasty form. Adherence will be compared between trial arm using baseline 
variables; and the reasons for withdrawal from treatment will be summarised.  
1.2.4 Loss to follow-up and other missing data 
Withdrawal from trial follow-up (attrition rate) will be reported by intervention group, 
including reasons for withdrawal. The proportions of participants missing each variable will 
be summarised in each arm and at each study visit.  
 
If necessary, multiple imputation will be used for the imputation of missing values in 
baseline variables and secondary outcomes. Patients with TLPP at the end of follow up will 
be considered censored, as will those who receive a renal transplant, switch to peritoneal 
dialysis or are lost to follow up before the study end.   
 
The baseline characteristics and adverse events of patients lost to follow up will be 
compared to those with complete follow up data. The relationship between these and 
missing data will be investigated graphically to see if baseline characteristics or adverse 
events predict missing, i.e. drop-outs are not random. 
1.2.5 Adverse event reporting  
Adverse events (AE), adverse reactions (AR), serious adverse events (SAE) and serious 
adverse reactions (SAR) will be summarised by trial arm and overall. 
1.2.6 Assessment of outcome measures (unblinding) 
Outcome assessors and the trial statistician are being kept blind to treatment allocation.  
1.2.7 Descriptive statistics for outcome measures  
The primary and secondary outcomes as listed in section 1.1.8 will be described by 
treatment group and time point. Means and standard deviations or medians and 
interquartile ranges will be used for continuous variables, where relevant; this will check 
whether continuous outcomes can be assumed normally distributed. Kaplan-Meier plots, 
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hazard-ratio and its confidence interval will be used to describe the time to event results. 
Frequencies and proportions will be used to describe binary variables. 
1.3 Data analysis plan – Inferential analysis  
1.3.1 Aims of formal inferences 
The formal statistical analyses will estimate the differences in relevant variables (time to 
event, quality of life) between patients randomised to the paclitaxel-coated balloon 
angioplasty compared to high-pressure placebo balloon angioplasty, by intention to treat. 
 
As mentioned in section 1.2.4, for the primary outcome and other time to event variables, 
patients lost to follow-up will be right censored; this means they are counted as not having 
experienced end of target lesion primary patency, or the relevant event, for the period of 
time we have data on them. If dropout is related to both outcome and treatment, then 
dropouts may bias the results. 
 
Group difference estimates and associated 95% confidence intervals will be reported. The 
trial statistician will remain blind until the main analyses have been completed. The overall 
significance level will be 5% (two-sided) for the primary and secondary outcomes. 
Significance level of final analysis of primary outcome will be determined by the alpha 
spending function used to plan interim analyses.  
 
Details on the methods for handling missing data are given in sections 1.3.8.  
 
Sensitivity analyses will be used to assess the robustness of conclusions; please refer to 
section 1.4 for details of the planned sensitivity and subgroup analyses. 
1.3.2 Analysis of the primary outcome 
The analysis population will include all patients randomised with sufficient information to 
carry out the analysis, i.e. complete primary outcome data and minimisation factors. The 
primary outcome is time to end of target lesion primary patency (TLPP); measured as days 
post randomisation. For the purpose of the primary outcome analysis, this will be taken as 
recorded by the target lesion primary patency form.  
 
Expected time to end of TLPP will be calculated using the hazard ratio estimated by the 
model explained below. Survival analysis methods will be used to compare the primary 
outcome for the two groups as this can factor in censoring and time.  
 
Kaplan-Meier plots will be used to graphically illustrate and compare the observed 
probabilities of target lesion primary patency past certain times in the trial period, taking 
into account censoring, for the two trial arms. This is a non-parametric estimate of the 
survival function over the analysis time, and will also be used to check the Cox 
proportionality assumption – see section 1.3.10.  
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Cox-Proportional Hazards regression will be used to model the effect of predictors and 
covariates on the hazard rate and estimate the relative risk by trial arm. This will be 
compared to an initial estimate from the null model where the model will be fitted without 
any covariates. Model components included in the primary model will be a baseline hazard 
function that is unspecified but positive; previous radiological intervention in the access 
circuit; on haemodialysis at randomisation; trial arm; observed study time (length of time 
between patient entering and exiting study); and a trial arm*observed time interaction 
term. The interaction term allows for variable follow-up time effects. 
 
A secondary adjusted analysis will be fit to evaluate the impact of baseline covariates on the 
size of the treatment effect. The covariates considered will be: baseline characteristics 
(ethnicity; age; diabetes diagnosis; and smoking history) and clinical variables at baseline 
(total time on haemodialysis; time since end stage kidney failure; type of native fistula; 
previous circuit intervention; and location of stenosis). 
 
The relationship between baseline variables and missing outcome data will be assessed 
using logistic regression with an outcome variable that represents whether outcome data 
are present or missing. Should any baseline variables be predictive of missing then these will 
be included in the primary analysis Cox regression models as further covariates.  
1.3.3 Interim analysis 
Interim analysis of the primary outcome will be performed up to three times throughout the 
study, based on the cumulative number of failures in the primary outcome, i.e. after 27, 54 
and 81 events, expected approximately at 9, 14 and 19 months of study under the null, and 
at months 11, 17, and 23 under the alternative hypothesis. Group sequential stopping 
boundaries have been calculated using a Lan-de-Mets spending function (with O’Brian-
Fleming parameters), to allow early stopping for rejection of the null or the alternative 
hypotheses. Stopping in case of boundary crossing is non-binding and will be discussed with 
the DMEC members during a closed session that does not include any trial members who 
are blinded. 
 
The Hazard Ratio used to evaluate the crossing of stopping boundaries will be calculated 
with a Cox-proportional hazards regression that includes presence or absence of previous 
interventions and currently on haemodialysis or not as covariates, as well as treatment 
group as independent variable of interest.  
 
Stopping boundaries are displayed in the figure below: 
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The table below shows further details of the stopping boundaries, including expected 
probability of crossing at each interim, and cumulative Alpha and Beta spent. Stopping 





Test statistics for interim analysis will be calculated with standard statistics software 
packages (R or Stata).  
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Interim analyses will be programmed by the trial statistician, and run and using the partially 
blinded randomisation sequence (trial arm numbers 1 or 2). The results will be presented to 
the DMEC in a partially blind report, and full unblinding of the code will only be provided to 
the members if they request it. 
1.3.4 Analysis of secondary outcomes 
Secondary patient outcomes relating to time-to-event variables, for example, time to end of 
access circuit primary patency, will be analysed using Cox regression models in a similar 
method to above.  
 
Continuous variables such as POS-S Renal score for quality of life, will be checked for 
normality, transformed if necessary and analysed using linear regression models. Otherwise, 
they will be analysed using a Wilcoxon-signed-rank test for independent samples. Logistic 
regression models will be used for binary secondary outcomes, for example, procedural 
success (rate of binary angiographic re-stenosis ≥50%) at the six month protocol fistulogram. 
 
Similarly to the primary outcome analysis, covariates considered in the models will include: 
baseline measure of outcome variable, where applicable; minimisation factors; trial arm; 
and time in study. An interaction term will also be included between observed study time 
and study treatment, as above. 
1.3.5 Stratification and clustering 
Randomisation is on the patient level, minimising on radiologist performing the study 
treatment and previous radiological intervention to treatment area or not; therefore these 
variables will be included as covariates in the modelling process, as mentioned in section 
1.3.2. However, the data should not have a clustered structure so this does not need to be 
accounted for. 
1.3.6 Missing items in scales and subscales 
The number (%) with complete data will be reported.  The ideal approach would be to use 
missing value guidance provided for scales.  
1.3.7 Missing baseline data 
We do not anticipate missing values in pre-randomisation variables. However, if we 
encounter missing baseline values then these can be singly imputed without incurring bias 
of the treatment effect estimate (White & Thompson, 2005). 
1.3.8 Censoring and missing outcome data  
For time to event outcomes, patient data is considered censored when the patient is 
withdrawn from follow-up, i.e. it is only known that the amount of time to event for that 
patient is greater than some value. Censoring will also happen at the end of the study, if the 
patient does not experience the primary endpoint before end of follow-up. In the analysis, 
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the censored observations will be included in the number of patients at risk in respect to 
their observed study time (survival time).  
 
For non-time to event outcomes, missing post-randomisation assessments will be dealt with 
by fitting generalised linear models to all the available data using maximum likelihood 
methods. Such an approach provides valid inferences under the assumption that the missing 
data mechanism is ignorable (or MAR). This allows for missingness at later times to be 
predicted by outcome values at earlier times. However, if post treatment variables such as 
compliance with study procedures are found to be predictive of drop out, multiple 
imputation will be considered. 
1.3.9 Method for handling multiple comparisons  
Analysis of secondary outcomes is considered exploratory, and therefore there will be no 
correction for multiple testing. However, care should be given to the interpretation of 
inference for the numerous secondary outcomes and it may be necessary to assess the 
agreement between similar outcome measures. Cohen's Kappa statistic and/or Spearman’s 
rank correlation coefficients may be used to test for inter-participant reliability and to 
measure the degree of linear association between two outcomes. For example, 
angiographically determined late lumen loss and the rate of binary angiographic re-stenosis 
would be expected to be highly predictive of one another.  
1.3.10 Method for handling non-compliance  
In addition to the primary intention-to-treat analysis the effect of actually receiving 
treatment as defined in the protocol will also be estimated. 
 
There is not expected to be a problem with non-compliance due to the design of the trial. 
1.3.11 Model assumption checks  
In order to assess the adequacy of the Cox regression models for the primary outcome and 
time-to-event secondary outcomes, the main assumption to test for is proportionality; the 
Kaplan-Meier plots will be used to check if the curves for the two trial arms are the same 
shape, and if the separation of the curves remains proportionate throughout the analysis 
period.  
 
In addition, time-dependent covariates will be generated by creating interactions of the 
predictors and function of survival time; if these are significant then the predictors are not 
proportional.  
 
If the assumption for proportionality is violated then the consequence this has on the 
results can be checked. The Cox model can be stratified according to the variables with non-
proportional hazards to see whether that changes the hazard ratios for the variables of 
interest; if it still does, then it may be necessary to use an alternative model. One 
parametric alternative is the Royston-Parmar model, which is more flexible and can fit a 







Figure 3.    
Severity and type of adverse event by treatment group. PC: paclitaxel-coated balloon group; S: standard 
balloon group. This bar chart illustrates the main types of adverse events that were reported by patients 
during follow-up, by treatment group and maximum severity. Patients can be included in more than one type 
of event, but if they experienced a certain event type more than once, then they have only been counted 
once for that event, and the maximum severity that they reported for that type of event has been used. 
Please note: this graph does not include deaths that occurred after patients formally withdrew from the trial; 
CVC: central venous catheter. 
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For the other secondary outcomes regression residuals will be plotted to check for normality 
and outliers, where applicable. 
1.4 Sensitivity analyses  
1.4.1 Planned sensitivity analyses 
A sensitivity analysis will be performed using adjudicated data from the core lab readings, in 
comparison to the primary analysis where the events reported in the trial will be used. This 
will assess the robustness of the trial findings by clarifying whether the primary analysis 
conclusions are impacted by any methodological issues, such as outcome definitions. 
1.4.2 Planned subgroup analyses  
Subgroup analyses will be carried out to assess whether the observed effect is consistent 
across patient categories; to do this, an interaction term will be included in the Cox 
proportional hazards model between the exposure (study treatment group) and the 
subgroup variable. 
  
The planned subgroups will be: second minimisation factor (previous radiological 
intervention to the treatment area or not); smoking history (current smoker, former 
smoker, never smoked); baseline diabetes diagnosis (yes, no); current total time on 
haemodialysis (quartiles); total time since end stage kidney failure (quartiles); type of native 
fistula (Radio-cephalic, Brachio-cephalic, Basilic vein transposition, Ulnar-cephalic); and 
location of stenosis (juxta-anastomotic, venous segment, cephalic arch, between cephalic 
arch and thoracic inlet).  
1.4.3 Competing risks analyses 
To assess the influence of events that may prevent other events from being observed, 
competing risks analyses will be planned to adjust for these. Specifically, ‘irrelevant’ deaths 
and re-transplantations will be defined as competing risks rather than censored events. The 
cause of death will be checked from hospital notes and/or death certificates. 
1.4.4 Exploratory analyses  
 
This analysis plan does not cover secondary exploratory analysis. Exploratory mediator and 
moderator analyses may be performed after the primary trial data analysis. 
1.5 Software 
Data management: An online data collection system for clinical trials (MACRO; InferMed 
Ltd) will be used. This is hosted on a dedicated server at KCL and managed by the KCTU.  The 
KCTU Data Manager will extract data periodically as needed and requests will usually be 
made by the trial statistician. There will be several database extracts throughout the trial for 
each DMEC Report, and a final extract after data lock. Data will be provided in comma 
separated (.csv) format.  
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Statistical analysis: Stata and or R will be used for data description and inferential analysis.   
 
1.6 Changes to version 
1 Since Version 1.0 the Trial Manager(s) have changed, and this has been updated 
2 Due to the recruitment period taking longer than planned, and including more hospital 
sites than originally expected, clarification has been made to the following sections in 
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01. Registration form 5 X                
02. Eligibility form  14 X                
03. Medical History form  19 X                
04. Haematology and 
Biochemistry form 
11 X  X X X            
05. Pre-procedure Fistulogram 
form 
8  X                   
06. Randomisation form 4  X               
07. Treatment Fistuloplasty 
form 
46  X               
08. Fistula Intervention form 
(repeating) 
32                X 
09. Month 6 Fistula Function 
form 
9     X            
10. Protocol Fistulogram form  11     X            
11. POS-S Renal questionnaire 25 X    X  X          
12. EQ-5D questionnaire 6 X    X  X          
13. Medications form 17 X   X X X X X X X X X X X X  
14. Adverse Events form 9                X 
15. Withdrawal form 5                X 
16. Status form 5    X X X X X X X X X X X X  
17. Loss of Patency form 
(repeating) 
9                X 
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